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ABSTRACT 
 
       HIV/AIDS had caused more than 25 million deaths since it was first recognized. 
Women are more susceptible to HIV infection in comparison with men due to human 
physiology, social, economic disadvantages. To protect women from HIV transmission, 
there is an urgent need to develop a formulation with proper vaginal retention time for the 
topical application of anti-HIV microbicides. The aim of this dissertation is to test the 
hypothesis that a mucoadhesive polymer based nanomedicine can prolong the contact 
time with the vaginal tissue, provide the controlled release of the drug, and is safe in vivo. 
Various formulation and are investigated, their physicochemical properties, 
mucoadhesive properties, and safety are evaluated.  
       In Chapter 3, a chitosan (CS) based nanoparticle (NP) delivery system suitable 
for the encapsulation of tenofovir (TFV) is designed and optimized. The physicochemical 
characteristics of the NPs including encapsulation efficiency (EE%), diameter, 
morphology, in vitro drug release as well as in vitro cytotoxicity are evaluated. the size of 
CS NPs ranged from 168 nm to 277 nm. It is shown that NPs are safe to both vaginal 
epithelial cell line and Lactobacillus over 48 h. The mucoadhesion is about 12%. The CS 
NPs are mucoadhesive and safe as a microbicide carrier, the drawback of the CS NPs is 
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the low EE%.  
In Chapter 4, the hypothesis that TFV loaded thiolated chitosan (TCS) NPs 
exhibit superior biophysical properties for mucoadhesion compared to those of native 
chitosan NPs is tested. The NPs are prepared by ionic gelation. The particle mean 
diameter, EE%, release profile, in vitro cytotoxicity, cellular uptake, uptake mechanism, 
and percent mucoadhesion are assessed. The particles are spherical with diameters ranged 
from 148 nm to 255 nm. The EE% and drug loading is 25% and 1.62% (w/w), 
respectively. The NPs provide a controlled release over of the drug following Higuchi 
model. The TCS NPs are not cytotoxic to both vaginal epithelial cell line and 
Lactobacillus over 48 h. The cellular uptake is time dependent. It is mainly occurred via 
caveolin mediated endocytosis. The mucoadhesive properties of TCS NPs is 5-fold 
higher than that of CS NPs. Compare to the CS NPs, the TCS NPs exhibit relatively 
higher EE%, drug loading, and mucoadhesion. 
       In Chapter 5, we develop a TCS coated multilayer microparticles (MPs). Sodium 
alginate MPs are prepared by spray drying. The multilayer MPs are developed by coating 
the optimal alginate MPs with the TCS solution using a layer-by-layer method. The 
morphological analysis, drug loading, in vitro drug release, cytotoxicity, mucoadhesion 
and in vivo toxicity are evaluated. The MPs diameter ranges from 2 μm to 3 μm with a 
drug loading of 7-12% (w/w). The MPs show a controlled drug release. The MPs are 
found to have a high mucoadhesion (~50 folds at a higher ratio, and ~20 folds at a lower 
ratio of mucin: MPs) compare to non-layered sodium alginate MPs in both vaginal fluid 
and semen fluid simulant buffers. The multilayer MPs are non-cytotoxic to vaginal and 
endocervical epithelial cells. Histological analysis of the female C57BL/6 mice genital 
tract and other organs shows no damage upon once-daily administration of MPs up to 24 
h and 7 days. The drug loading of the TCS MPs is significantly enhanced (from 1.62% to 
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12.73%) compare to that of the TCS NPs. However, the mucoadhesion of the MPs is 
slightly lower than that of the NPs due to the larger particle size. 
In chapter 6, the TCS core/shell nanofibers (NFs) are fabricated by a coaxial 
electrospinning technique. The drug loading is13%-25% (w/w), the EE% is about 100% 
because no loss of material during the electrospinning process. The NFs exhibit smooth 
surface with average diameters in the range of 50 to 100 nm. The NFs are non-cytotoxic 
at the concentration of 1 mg/ml. The core-shell NFs exhibit a release kinetic following 
Weibull model, and are 40-60 fold more bioadhesive than NFs made solely with PEO. 
H&E and immunohistochemical (CD45) staining analysis of genital tract indicates 
non-toxicity and non-inflammatory effects of the NFs daily treatment for up to 7 days. 
The TCS NFs exhibit both high drug loading and high mucoadhesion; these data 
highlight the potential of TCS NFs templates for the topical vaginal delivery of 
anti-HIV/AIDS microbicides. 
Overall, the present work demonstrates TFV loaded NF can be considered as a 
good candidate for the delivery of water-soluble small-molecule drugs, and a promising 
vaginal delivery system for the prevention of HIV transmission. 
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CHAPTER 1 
INTRODUCTION 
1.1 Overview  
       HIV/AIDS had caused more than 25 million deaths since it was first recognized. 
Nowadays, HIV/AIDS is one of the most destructive epidemics recorded in history1. HIV 
infection rates have reached pandemic levels worldwide with the number of people living 
with HIV estimated more than 35 million2. Among these people, women represent a growing 
proportion, and the ratio of infected men to women is particularly skewed among young 
people3. Women are more susceptible to infection in comparison with men due to not only 
the human physiology, but also social, economic, and legal disadvantages, which limit their 
ability to protect themselves, especially in Asia and Africa3. In sub-Saharan Africa, for every 
HIV-infected young man (15–24 years old) there are nearly three infected young women4. 
Therefore, this is an urgent and critical need to identify effective strategies that can reduce 
women’s risk of HIV/AIDS and other sexually transmitted infections.  
More than 80% of HIV infections of women occur through heterosexual contact 
with an infected partner5. While unprotected heterosexual vaginal intercourse has become a 
predominant route of infection for this disease, a lot of studies have shown that the vagina is 
also a suitable site for the delivery of drugs6. The large surface area, permeability, and the 
rich blood supply of the mucous membrane of the vagina provide significant potential for the 
delivery of drugs7. Polymer-based nano- or micro-medicine has been considered in the intra 
vaginal delivery of microbicides as they could avoid the degradation, improve the uptake and 
allow sustained release of drugs8. Various formulations of this type have been developed. 
Recent advances have been made in the area of bioadhesive nanomedicine. Thiolated 
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polymer, so-called thiomer is a new generation of mucoadhesive polymers that can form 
covalent mucus bridging between thiomers and mucosa, leading to improved mucoadhesion. 
Thiomer based nanomedicines show great promise for use as controlled intra vaginal delivery 
systems. By prolonging the contact time of the microbicide with the vaginal tissue, the effect 
of the microbicide could be significantly improved. These improvements range from better 
treatment of local pathologies, to superior drug bioavailability, and controlled release to 
enhance patient compliance9.  
1.2 Research hypothesis 
       The research hypothesis of this study is that a thiolated chitosan based 
mucoadhesive anti-HIV nanomicrobicide delivery system is effective, safe and for HIV 
prevention in women (Fig. 1-1). 
 
 3
Fig. 1-1 Mucoadhesive nano-formulation for vaginal delivery of microbicide. 
1.3 Objectives˜The objectives of the dissertation are: 
(1) To design a chitosan (CS) based nanoparticle (NP) delivery system suitable for 
the encapsulation of ˜tenofovir (TFV). To optimize the preparation process and understand 
which variables can affect the NP mean diameter as well as drug encapsulation, Design of 
Experiment is used. The physicochemical characteristics of the NPs including encapsulation 
efficiency (EE%), diameter, morphology, in vitro drug release as well as in vitro cytotoxicity 
are evaluated.  
(2) To test the hypothesis that TFV loaded thiolated chitosan (TCS) NPs exhibit 
superior biophysical properties for mucoadhesion compared to those of native chitosan NPs. 
The NPs are prepared by ionic gelation. The particle mean diameter, EE%, release profile, in 
vitro cytotoxicity, cellular uptake, uptake mechanism, and percent mucoadhesion are 
assessed. 
       (3) To develop the thiolated chitosan coated multilayer microparticles (MPs) with 
enhanced drug loading. Sodium alginate MPs are prepared by spray drying. Formulation 
optimization is achieved through a custom experimental design. The yield of the MPs is 
evaluated as the dependent variables. The multilayer MPs are developed by coating the 
optimal alginate MPs with the TCS solution using a layer-by-layer method. The 
morphological analysis, drug loading, in vitro drug release, cytotoxicity, mucoadhesion and
in vivo toxicity are evaluated. 
     (4) To prepare the TCS core/shell nanofibers (NFs) that can enhance the loading of 
TFVF and improve the mucoadhesivity, Core/shell NFs are fabricated by a coaxial 
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electrospinning technique. The morphology, drug loading, drug release profiles, cytotoxicity 
and mucoadhesion of the NFs in vitro cytotoxicity and In vivo safety studies are carried out. 
       Overall, the present work aims to solve the following problems in the vaginal 
delivery of HIV microbicides, namely the lack of EE% and drug loading, the lack of 
retention time, and the lack of assurance in biosafety. 
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Normal vaginal physiology and environment 
In order to develop an appropriate drug delivery system for the prevention of HIV 
transmission through heterosexual route, an understanding about the vaginal physiology 
environment is necessary. The vagina is an 8-10 cm long fibromuscular canal, leading from 
the cervix to the outside of the body. From the lumen outwards, the first layer is a mucosa of 
the epithelium that lines the inner surface of the vagina. The vaginal fluid secretes by the 
epithelium lubricates the mucosa provides moist to the vaginal environment. For the healthy 
women, the pH of the vaginal fluid is normally 3.5-5.0. The acidic pH is attributed to the 
Lactobacillus, a predominant normal vaginal floral species, which is able to produce lactic 
acid and hydrogen peroxide (H2O2)10. The acidic pH can prevent the growth of yeast and 
bacteria, it is a natural barrier for HIV transmission. The epithelium is responsible for 
protecting from friction to the underlying layers, and therefore is multilayered, durable and 
relatively strong. The non-keratinized epithelium divides into columnar ecto- and 
endocervical epithelium gradually near the cervix, and keratinized epithelium resembling 
skin and covers the intriotus when it is close to the opening. Beneath the epithelial layer is 
the lamina propria, a layer of connective tissue with a lot of fibers allow the stretch of the 
vagina, several classes of lymphoid cell is within it, including Langerhans cells, dendritic 
cells, T lymphocytes and, macrophages. Most of these cells are potential target cells for HIV 
(Fig. 2-1). Deep to the lamina propria is a layer of smooth muscle tissue, surrounding by the 
outermost layer known as the tunica externa of the vagina11.  
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Fig. 2-1 Structure of the human vaginal epithelium.  
The integrity of vaginal epithelium is highly associated with the risk of vaginal acquisition of 
HIV. In case of an intact vaginal environment, the epithelium is responsible maintaining a 
functional immune response that against any genital pathogens. However, when the 
epithelium is damaged, HIV can penetrate the mucosa rapidly, transmit and infect the 
dendritic projection of Langerhans cells, followed by reaching the other target cells. 
       There are several other factors that may significantly increase the likelihood of HIV 
transmission, including the bacterial vaginosis12, dry or traumatic sex13, and vaginal 
inflammatory diseases14. These factors enhance the HIV vaginal transmission through 
disrupting the integrity of vaginal mucosal, alteration of normal vaginal pH or vaginal 
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microbiota, increasing the amount of HIV target cells, disrupting the H2O2 producing 
Lactobacillus bacteria, and thinning the cellular liningb[17]. After local infection, HIV can 
disseminate throughout the lymph nodes and secondary lymphoid organs to generate a 
systemic infection. 
2.2 Vaginal transmission of HIV 
       Multiple type of cells in human body HIV can be infected by HIV, CD4 lymphocyte is 
the main target. CD4 lymphocytes are infection-fighting cells made in spleen and lymph nodes. 
They can identify and destroy foreign particles such as viruses and bacteria, therefore is an 
essential part of the immune system. HIV goes through several steps to bind and then infect 
the CD4 cells. Once a CD4 cell is infected with HIV, the virus reproduces itself in the host cell, 
create and release more virus particles. The life cycle (Fig. 2-2) is broken up into the following 
steps15: 
(1) Binding: CD4 receptors express on the surface of CD4+ cells including 
macrophages, monocytes, T lymphocytes, and dendritic cells, it is an essential for the 
membrane fusion and entry of HIV. When HIV attacks a CD4+ cell, HIV gp120 binds to the 
CD4 receptor, and then binds to CCR5/CXCR4. 
(2) Fusion: The binding of gp120 to CCR5/CXCR4 coreceptor induces 
conformational changes in the viral gp120-gp41 glycoprotein complex, the N-terminal 
domain of gp41 is exposed so that the fusion peptide sequence can insert into the host cell 
membrane of the host cell. The N-terminal heptad repeat region and C-terminal heptad repeat 
region of the intra-gp41 protein folds together to form a hairpin structure, which allows the 
viral envelope to fuse with the CD4 cell membrane, which further enables the virus to enter the 
cell.. Once inside the cell, the HIV releases HIV RNA and enzymes, such as reverse 
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transcriptase and integrase. 
 
Fig. 2-2 Life cycle of HIV  
       (3) Reverse Transcription and integration: The reverse transcriptase converts 
single-stranded HIV RNA into double-stranded HIV DNA. This is called reverse 
transcription. Integrase is another enzyme released from HIV. With the help of integrase, HIV 
DNA enters the CD4 cell nucleus, and inserts itself into the host cell DNA.  
       (4) Replication: Once HIV genetic material is integrated into the host cell DNA, the 
virus begins to create new viral RNA using the machinery of the host cell. The newly formed 
multiple copies of HIV RNA move out of the nucleus, and produce viral proteins and 
enzymes, such as the viral envelope, reverse transcriptase and integrase, through the 
translation process. The new proteins and enzymes are the building blocks for more HIV.  
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(5) Assembly and budding: New HIV RNA proteins formed by the host cell move to 
the cell surface and assemble into immature HIV, which then pushes itself out of the CD4 cell, 
taking part of the cell membrane to covers it, and forms mature, infectious HIV. A single HIV 
infected cell can release a lot of new virus, which repeat the same life cycle and infect more 
cells. Eventually, the host cells are destroyed. 
2.3 Topical microbicides for HIV prevention 
Microbicide can kill or neutralize viruses by blocking the attachment of HIV to 
immune cells, inactivating or killing the virus, preventing the spreading infection to other 
cells, and strengthening normal defenses of the body. A great number of HIV microbicides 
candidates have been studied and tested16, more than 30 of them have been approved by the 
U.S. Food and Drug Administration (FDA). Due to the different viral cycle steps they target, 
these microbicides can be classified into several categories as follow17 (Tab. 2-1)18.  
(1) Entry Inhibitors: Interfere with the virus ability to bind to gp120 receptors on the 
outer surface of the CD4+ cell it tries to enter[49]. There are several subcategories such as 
gp120 inhibitors, gp41 inhibitors, CD4 inhibitors, CCR5 inhibitors, CXCR4 inhibitors. 
(2) Fusion Inhibitors: Binds to the HIV-1 membrane glycoprotein gp41 and prevents 
the conformational changes required for viral membrane fusion with the cells. This prevents 
HIV from entering a cell. 
(3) Reverse-transcriptase inhibitors (RTs), NRTIs act by blocking the RT enzyme. RTs 
have two subcategories: Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs). NRTIs are preferentially 
incorporated into HIV DNA, leading to termination of DNA synthesis; NNRTIs bind to a 
pocket near the active site, which causes a conformational change of the enzyme and 
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inhibition of reverse transcription19. 
       (4) Protease Inhibitors: Inhibits virus-specific processing of viral Gag and Gag-Pol 
polyproteins in HIV infected cells by inhibiting viral protease. 
 (5) Integrase Inhibitors: Block the action of HIV enzyme integrase, which the virus 
uses to integrate its genetic material into the DNA of the host cell. 
 (6) Capsid Inhibitors: Inhibitors of HIV-gag polypeptide assembly. Dismantles 
assembled HIV-1 capsid assembly tubes. 
Tab. 2-1 Classification of Anti-HIV Microbicide and their formulations. 
Category Microbicide Nature of the molecules Formulation 
RT NRTI Zidovudine* Small molecule Tablet 
Emtricitabine* Small molecule Capsule, Tablet 
Lamivudine* Small molecule Tablet 
Abacavir* Small molecule Tablet 
Zidovudine* Small molecule Tablet, oral 
solution, capsule
Tenofovir (TFV)* Small molecule Tablet 
Didanosine* Small molecule Capsule 
Tenofovir DF* Small molecule Tablet 
Stavudine* Small molecule Capsule 
NNRTI Rilpivirine* Small molecule Tablet 
Etravirine* Small molecule Tablet 
Delavirdine* Small molecule Tablet 
Efavirenz* Small molecule Tablet 
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Nevirapine* Small molecule Tablet 
Integrase Inhibitor Raltegravir* Small molecule Tablet 
Dolutegravir* Small molecule Tablet 
Protease Inhibitor Tipranavir* Small molecule Capsule 
Indinavir* Small molecule Capsule 
Cobicistat* Small molecule Tablet 
Saquinavir* Small molecule Tablet 
Lopinavir* Small molecule Tablet 
Fosamprenavir* Small molecule Tablet 
Ritonavir* Small molecule Tablet 
Darunavir* Small molecule Tablet 
Atazanavir* Small molecule Tablet, capsule 
Nelfinavir* Small molecule Tablet 
Entry 
Inhibitor 
gp120 
inhibitor 
b12 Monoclonal antibody Injection, gel 
2F5 Monoclonal antibody Injection 
4E102 Monoclonal antibody Injection 
P2G121 Monoclonal antibody intravaginal 
administration 
F1051 Monoclonal antibody Injection 
VRC011 Monoclonal antibody Injection, gel 
Pro-5422 Protein Injection 
M48UI Peptide Gel 
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gp120 and 
gp41 
inhibitor 
Cyanobactcrial Cyanobacterial protein Gel, Live 
bacteria 
Griffithsin Cyanobacterial protein Purified protein 
2G12, F105, 2F5 Monoclonal antibody Injection 
CCR5 
inhibitor 
Maraviroc* Small molecule Tablet 
PSC-RANTES, 
5P12-RANTES 
Peptide Purified peptide 
PRO1403 Monoclonal antibody Injection 
HGS0041 Antibody Injection 
CXCR4 
inhibitor 
AMD110702 Small molecule Tablet 
CD4 
inhibitor 
Ibalizumab2 Antibody Injection 
Fusion Inhibitor T-20* Peptide Injections 
T-12492 Peptide Injection 
Sifuvirtide2 Peptide Injection 
Capsid Inhibitor     
   
* FDA approved, 1 Clinical trial Phase 1, 2 Clinical trial Phase 2, 3 Clinical trial Phase 3. 
 
       Among the above microbicides, TFV is selected as a model drug in this study. TFV 
is classified as NRTIs, in order for HIV to be incorporated into the host’s genomic DNA, a 
copy of viral RNA must be made, which is facilitated by reverse transcriptase. TFV inhibits 
enzyme activity by attaching to its active site, subsequently disabling the binding of the 
natural substrate deoxyadenosine 5’-triphosphate. Once TFV is inserted into the viral DNA, 
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the normal 5’ to 3’ links are prevented from occurring, resulting in HIV DNA chain 
termination20. The FDA approves TFV for the treatment of HIV infections in October 2001. 
Numerous formulations of tenofovir have been prepared to prevent the male to female sexual 
transmission of HIV, such as gel and the intravaginal ring21.  
       Although the oral drug delivery route is the most preferred and convenient route of 
administration, it has limitations such as:  
(1) Hepatic first-pass metabolism and enzymatic degradation within the 
gastrointestinal (GI) tract. 
(2) Absorption limitation of drugs due to their physico-chemical characteristics 
(3) Possible of gastrointestinal mucosa irritation5. 
(4) Ciliary clearance and transit of food can limit the retention of drug in the GI 
track. 
 More than 80% of HIV infections of women occur through sexual contact with an 
infected partner5. While unprotected heterosexual vaginal intercourse has become a 
predominant route of infection for this disease, a lot of studies have shown that the vagina is 
also a suitable site for the delivery of drugs6. The large surface area, permeability, and the 
rich blood supply of the mucous membrane of the vagina provide significant potential for the 
delivery of drugs7. For the delivery of a female controlled anti-HIV microbicide, vaginal 
administration offers many advantages over systemic delivery such as the oral and injection 
route:  
(1) Potential for non-invasive, controlled delivery of drugs. 
(2) Vaginal route prolonged the contact of the drug delivery system with the mucosa 
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may be achieved more easily than that of the GI tract. 
(3) The possibility of maintaining the drug delivery system in the site of application 
for extended periods of time, thereby reducing the dosing frequencies. 
(4) Vaginal route provides higher local concentration of drug, and thereby reduces the 
systemic side effect. 
(5) Good permeability to a wide range of compounds including both small molecules 
and large molecules. 
(6) Avoidance of the caused by pain, tissue damage and other inconvenience 
associated with parenteral routes. 
       To achieve a significant effect, the ideal vaginal microbicide formulation should 
have high vaginal retention time, high drug loading and be able to release a high dose of 
microbicides in a short period of time when required. Several important properties for 
vaginal microbicide formulation products with regard to their safety and efficacy have been 
established as shown in Tab.2-217, 18b, 22. 
Tab. 2-2 Critical characteristics of ideal vaginal microbicide formulations 
Properties  Acceptable  Unacceptable 
Safety • Lack of localized/systemic 
toxicity. 
• inertness towards the normal 
vaginal microbiota. 
• Have no-effect on fertility 
and/or fetal abnormalities. 
• Induce epithelial disruption 
• Cause inflammation 
• Absorbed systemically 
Activity • Efficient in preventing HIV • Affect normal vaginal (rectal) 
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transmission. 
• Active against a range of 
sexually transmitted 
pathogens. 
microbial ecology 
• Enhance growth of secondary 
pathogens or sexually transmitted 
infections or  
• Induce drug resistance. 
Effective • Fast 
• long-term efficacy  
• Irreversible 
• Interval of efficacy between 
application and intercourse 
Stability 
 
• stable under diverse 
environmental conditions. 
• Requires special storage/transport 
• Short half-life in vivo 
Acceptability • Acceptable to the user and 
user’s sex partner 
• Less administration times daily 
• Extended periods of use 
• Affordable by high-risk 
populations 
• Leaky, Messy, 
• Burning, itching 
• Interfere with sexual pleasure 
• Cumbersome Delivery vehicle 
• Taste / odor / texture / color 
• Costly for use and/or manufacturing 
Uses • Vaginal and/or rectal 
• Unlimited use 
• Compatible with condoms 
and other STI prevention 
methods 
• Complicated use 
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2.4 Mucoadhesive drug delivery system 
       Mucoadhesion can be defined as the interfacial forces by which a biological material 
and mucus layer are held together. When this concept is applied to pharmaceutical 
formulation, the mucoadhesive molecules is incorporated into drug delivery systems, so that 
it intends to maintain together with mucosa for a prolonged time period, and release the drug 
near the site of action. Some of the market available mucoadhesive vaginal formulations are 
summarized in Tab. 2-3. 
Tab. 2-3 Marketed mucoadhesive vaginal products. 
Brand name Active pharmaceutical ingredient Formulation 
Prochieve® Progesterone Gel 
Aci-Jel® Acid-buffering Gel 
Buffer Gel® Acid-buffering Gel 
Metrogel Vaginal® Metronidazole Gel 
PRO 2000/5® 2-Naphthalene sulfonic acid Gel 
K-Y Jelly® Glycerin and Hydroxyethyl cellulose Gel 
Clomirex® Chlorhexidine Gel 
Mifluor® Fluor Gel 
Advantage S® Nonoxynol-9 Gel  
Conceptrol® Nonoxynol-9 Gel 
Gynol II® Nonoxynol-9 Gel 
Gynazole® Butoconazole Cream 
Replens® Glycerin Moisturizer 
Prostin E2® Dinoprostone Suppository 
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Vagifem® Estradiol Vaginal tablet 
 
Currently, most commercially available formulations conventional drug delivery 
system. However, they all suffer from several limitations. A lot of the emphasis has been put 
on the gel and cream formulation23. Although they are female controlled and easy to 
formulate, the trouble includes: messy and leakage out of the vaginal cavity, limitation of 
encapsulating hydrophobic drugs; the low retention time requires a high dosing frequency, 
which leads to significant patient compliance issues24; Non-uniform distribution; poor 
acceptability and adherence. In the case of solid dose, such as tablets and suppositories, the 
advantages are no leakage, and no applicator required, however, they may leave a grainy 
residue after application in the vaginal cavity; contact of solids can result in vaginal 
epithelium irritation; disintegration of the product depends on local hydration.  
       These limitations can be solved by novel nano-formulations, which is the medical 
application of biological materials and nanotechnology. Nanomedicines can provide 
sustained drug release, which is necessary for maintaining effective concentration of drug 
between the time of application and intercourse and therefore reducing the dosing frequency.  
Nanomedicines are nanoscopic or microscopic drug carriers, patients feel neither leakage nor 
residue due to their tiny size, as a result, the patient compliance can be improved. Moreover, 
nano-formulations have the ability to encapsulate both hydrophilic and hydroponic drugs. 
Due to the above properties, nanomedicine is a promising vehicle for vaginal delivery of 
microbicides. 
       Most nanomedicines are polymer based. To select a proper mucoadhesive polymer, 
it is necessary to understand the mucoadhesion theory. After the initial contact between the 
two surfaces, the surface force between the chemical structures, due to one or more 
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secondary forces such as hydrophobic bonding, hydrogen bonding, and van der Waal’s 
forces25. A system for mucoadhesive polymers can be categorized due to the mechanism of 
mucoadhesion. Their principles of mucoadhesion include: 
Diffusion theory of mucoadhesion: In the case of diffusion theory, the driving force 
of penetration is the concentration gradient. The polymer chains form the semi-permanent 
bond chain with glycoprotein mucin chains. After an intimate contact is established, chains 
move into the opposite phases along the concentration gradients. A depth of 0.2–0.5 mm is 
needed for effective bioadhesive bonds. The depth of diffusion is dependent on the molecular 
weight, which can influence the diffusion coefficient26. 
Wetting theory of mucoadhesion: The key element of the Wetting theory is the 
embedding process. Polymers penetrate into surface irregularities of the mucin and then 
produce adhesive anchors. The adhesive force is related to the surface tension of both 
phases27. 
Electrostatic theory of mucoadhesion: Following the electrostatic theory, the 
adhesive force is generated by transferring of electrons along the adhering surface and the 
adhesive interface. The contact between the two layers is maintained by a series of attractive 
forces26. 
       Based on their surface charge surface, which plays a key role in the binding 
mechanism. Mucoadhesive polymers can be classified into two major types: anionic 
polymers and cationic polymers, some important anionic polymer and cationic polymers are 
shown in Tab. 2-4.  
Tab. 2-4 Commonly used anionic and cationic polymers 
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Category Polymer Structural formula 
Anionic 
mucoadhesive 
polymer 
 
Alginate 
Hyaluronic acid 
Carboxymethylc
ellulose 
        
Pectin           
 
Cationic 
mucoadhesive 
polymer 
 
Chitosan                  
 
Polylsyine                   
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       The carboxylic moiety (–COOH) of anionic polymers is mainly responsible for 
mucoadhesion28.  The carboxyl groups can form hydrogen bonds with the hydroxyl groups, 
which presents on the side chains of the oligosaccharide on mucus proteins. For cationic 
polymers, their mucoadhesive properties are due to ionic interactions between cationic 
polymers and anionic sialic acid groups of the mucus gel layer. Among all cationic polymers, 
chitosan is a potential representative, it is most commonly used polymer with high 
mucoadhesive properties. 
Thiolated polymer, so-called thiomer is a new generation of mucoadhesive polymers. 
Thiomers form covalent mucus bridging between thiomers and mucosa, leading to improved 
mucoadhesion. Nowadays, thiomers have been widely used in vaginal delivery with 
enhanced mucoadhesion. 
As shown in Fig. 2-3, thiomers display thiol bearing side chains that mimic the 
natural mechanism of secreted mucus glycoproteins29. Based on thiol/disulfide exchange 
reactions, and/or a simple oxidation process, disulfide bonds are formed between polymers 
and cysteine-rich subdomains of mucus glycoproteins so that the polymers can covalently 
anchor in the mucus layer30. In this study, thiolated chitosan is used as a mucoadhesive 
material in the nanomedicines for the vaginal delivery of anti-HIV microbicide. 
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Fig. 2-3 Formation of the disulfide bond between mucin and thiomer by thiol/disulfide 
exchange reactions, and oxidation process. 
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CHAPTER 3 
ENGINEERING TENOFOVIR LOADED CHITOSAN NANOPARTICLES FOR THE 
PREVENTION OF HIV TRANSMISSION 
3.1 Rationale 
       As one of the most promising drug delivery systems, polymeric nanoparticles (NPs) 
have been studied extensively and intensively in recent years31. Several polymeric 
nanoparticulate systems have been prepared and characterized based on both natural and 
synthetic polymers. Among these polymers, chitosan attracts considerable attention because 
of its applicable physicochemical and biological properties32. 
       Chitosan is a water-soluble, linear amino polysaccharide, which is composed of 
2-amino-2-deoxy-β-D-glucan combined with glycosidic linkages33. It can be obtained by the 
deacetylation of chitin, which is one of the most abundant natural polysaccharides found in 
the exoskeletons of crustaceans, such as shrimp and lobster34. 
       Chitosan exhibits many advantages in developing NPs, including biocompatibility, 
biodegradability, and low-immunogenicity35. The high positive charge density also confers 
its mucoadhesive properties36, and make it an ideal candidate for the delivery of drugs to 
mucosal tissues37. Chitosan also has a very low toxicity. Its LD50 in laboratory mice is 16 
g/kg body weight, which is close to sugar and salt35a. 
       In comparison with many other polymers, the chitosan backbone contains a number 
of free amine groups, which makes it used extensively in drug delivery applications. In an 
acidic environment, the amino groups could be positively charged after protonation. 
Therefore, chitosan is able to interact with negatively charged molecules38. Sodium 
tripolyphosphate (TPP) is a polyvalent anion with three negatively charged phosphate groups. 
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This property enables it to work as a cross linking agent of chitosan. NPs could form 
spontaneously in mixed TPP and chitosan solutions through inter and intra molecular 
linkages created between TPP phosphates and chitosan amino groups38. These types of 
nanoparticulate systems have shown a high affinity for the association of negatively charged 
macromolecules39, such as the mucin that are present on the mucosal surface. 
       Tenofovir (TFV) is a water-soluble, small-molecule drug, which contains a 
phosphate group and is negatively charged in a NaOH solution. It can also interact with 
chitosan through electrostatic forces. The use of complexation between oppositely charged 
macromolecules to prepare chitosan NPs has attracted much attention. This technique has 
been previously adapted for the encapsulation of peptides and proteins38. This study aims for 
the preparation of TFV loaded NPs through the ionic cross-linking of chitosan, which is a 
kind of physical cross-linking induced by electrostatic interaction. In comparison with 
chemical cross-linking, it is advantageous because the process is simple and carried out under 
mild conditions without using hazardous organic solvents40. Thus, it has better 
biocompatibility than covalently cross-linked chitosan, and it is possible to reduce the 
potential toxicity35a, 41. 
3.2 Materials and methods 
3.2.1 Materials 
       The chitosan (deacetylation degree of 0.92 and molecular weight of 50,000-190,000 
Da) and sodium triphosphate pentabasic (TPP) are purchased from Sigma Aldrich (St. Louis, 
MO, USA). TFV (99% purity) is purchased from Zhongshuo Pharmaceutical Co. Ltd. 
(Beijing, China). Acetic acid is supplied by Fisher Scientific (Pittsburgh, PA, USA). 
CytoTox-ONE™ reagent and CellTiter 96® Aqueous One Solution Reagent is purchased 
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from Promega (Madison, WI, USA). All chemicals used in the study are of analytical grade 
and used as received without further purification. 
3.2.2 Method 
3.2.2.1 Box–Behnken experimental design 
       A Box–Behnken statistical design with three levels, three factors, and 15 runs is 
used to design the experiment to optimize the preparation conditions. Some of the 
polynomial Equations relating factors and responses are obtained by Box–Behnken design 
software (JMP 8, SAS Institute, Cary, North Carolina, USA). 
       As shows in Tab. 3-1, the three key formulation variables (concentration of chitosan, 
weight ratio of TPP and chitosan, weight ratio of drug and TPP) are represented by X1, X2, 
and X3, respectively. The evaluated responses (encapsulation efficiency and particle size) are 
represented by Y1 and Y2, respectively42. 
Tab. 3-1 Independent variables and their levels in Box-Behnken design 
Independent variables Low Medium High 
X1= concentration of chitosan (w/v %)* 
X2=TPP/chitosan (w/w) 
X3=drug/chitosan (w/w) 
Coded values 
0.1 
0.1 
0.1 
-1 
0.2 
0.2 
0.2 
0 
0.3 
0.3 
0.3 
1 
Dependent values  
Y1= encapsulation efficiency (EE, %) 
Y2= size (nm) 
* The volume of chitosan is 10 ml  
3.2.2.2 Preparation of CS Based NPs 
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       The preparation of CS NPs is adapted from a previously described method43. Briefly, 
chitosan is dissolved in 10 ml of acetic acid (1% v/v) at different concentrations. TPP is 
dissolved in 1 ml of purified water at various concentrations in order to obtain the final ratio 
shown in Tab. 3-1 The TPP solution is added in a chitosan solution during magnetic stirring 
at room temperature, spontaneously forming an opalescent suspension. 
       For the preparation of TFV loaded NPs, TFV is dissolved in 2 ml of 0.5 M NaOH. 
Then the drug solution is dropped into the chitosan solution during magnetic stirring, 
followed by the addition of the TPP solution. The pH of the mixture is adjusted between 5 to 
6.5 under continuous stirring for 10 min at room temperature. 
       Chitosan can dissolve in a mixture of acetic acid (1% v/v) and ethanol44. Therefore, 
in this experiment, beside 1% v/v acetic acid used alone, the solvent mixtures are made of 
ethanol in 1% acetic acid solution in various ratios (25 and 50%v/v). 
       NPs are recovered by centrifugation at 20,000 rpm and 20 °C for 60 min (Beckman 
L8-70 M Ultracentrifuge, Brea, CA, USA). The supernatant is used to determine the drug 
EE%. The deposited NPs is washed three times by deionized water, and is freeze-dried 
(Labconco Corperation, Kansas City, MO, USA) and stored at 4 °C–8 °C. 
3.2.2.3 Particle size determination 
       Different NPs samples are resuspended by sonication (Qsonica LLC, Newtown, CT, 
USA) in distilled water, and the particle size and polydispersity index is determined through 
dynamic light scattering (Zetasizer Nano ZS, Malvern Instruments Ltd, Worcestershire, UK) 
at the temperature of 25°C. Samples with PI < 0.05 are considered monodispersed according 
to the National Institute Standard45. 
3.2.2.4 Encapsulation efficiency (EE%) 
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       The content of TFV is calculated from the difference between the total amount of 
drug added in the NP preparation and the amount of free drug in the supernatants. The 
amount of unencapsulated drug is measured by UV spectrophotometer (Spectronic Genesys 
10 Bio, Thermo Electron Corperation, WI, USA) at a wavelength of 259 nm. The drug EE% 
is calculated as follows: 
       
Total amount of tenofovir-Free tenofovir
% 100
Total amount of tenofovir
EE  u       (3-1) 
3.2.2.5 Morphological analysis  
       The transmission electron microscopy (TEM) is used to assess the morphology of 
NPs. To obtain the specimens, drops of NP suspension are placed on a copper grid with a 
carbon support film and air dried. The NPs are viewed under a Scanning Transmission 
Electron Microscope CM12 (FEI, Hillsboro, OR, USA) at 80 kV accelerating voltage. Digital 
images are acquired with an ORIUSTM SC 1000 11 Megapixel CCD camera (Gatan, 
Pleasanton, CA, USA). 
3.2.2.6 In vitro release study 
       Two milliliters of the NP suspension is put into a Spectra/Por cellulose ester 
membrane dialysis bag (Spectra/Por Float-A-Lyzer G2, MWCO 3.5-5 KD, Spectrum 
Laboratories Inc. Rancho Dominguze, CA, USA), and immersed into 20 ml of vaginal fluid 
stimulant (VFS) that is prepared according to previous reports45-46. The media is incubated in 
a thermostatically controlled shaking (60 rpm) water bath (BS-06, Lab Companion, Seoul, 
Korea) at 37 ºC. At predetermined time intervals, all the buffer solution outside the dialysis 
bag is removed and replaced by fresh buffer solution to maintain a sink condition. The 
concentration of the drug in the solution is determined by a UV spectrometer at 260 nm. Each 
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experiment is run in triplicate together with a blank. 
3.2.2.7 Cell culture  
3.2.2.7.1 Lactate dehydrogenase (LDH) sssay 
       The vaginal epithelial cells are seeded in a 96-well plate. The medium is changed 
with 100 μl medium with chitosan NPs of different sizes. The concentration of NPs is 1 
mg/ml. A medium without NPs is used as negative control, and 1% Triton X is used as 
positive control. A row of wells without cells is used to determine the background fluorescent 
that might be present due to media only. The plate is incubated at 37 °C for 4 and 48 h, and 
then equilibrated to 22 °C. 
       One hundred microliters (100 μl) of CytoTox-ONE™ reagent (Promega, Madison, 
WI, USA) is added to each well and shaken for 30 seconds. The plate is incubated under 
22 °C for 10 min, and then 50 μl of stop solution is added to each well. The fluorescence is 
determined by a DTX 800 multimode microplate reader (Beckman Coulter, Brea, CA, USA) 
at an excitation wavelength of 560 nm and an emission wavelength of 590 nm. The percent 
cytotoxicity of can be expressed as: 
       
(%) 100
Experimental Background
Cytotoxicity
Positive background
 u      (3-2) 
       Where Experimental is the absorbance of NP-treated wells, Background is the 
absorbance of background wells (wells without cells), and Positive is absorbance of positive 
control wells (cells treated with 1% Triton X). 
3.2.2.7.2 MTS assay 
       Cell viability is determined by adding MTS and then checking the amount of the 
colored formazan product that is bioreduced from the MTS by the cells. Cells are seeded and 
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incubated with NPs under the same condition as above following the manufacturing protocol. 
At different intervals, NP suspension is removed and substituted with fresh medium. Twenty 
microliters of CellTiter 96® Aqueous One Solution Reagent (Promega, Madison, WI, USA) is 
added to each well and incubated at 37 °C for 4 h. The absorbance is recorded at a 
wavelength of 490 nm. 
        
(%) 100Test
Control
ABS
Viablility
ABS
 u        (3-3) 
where ABSTest and ABSControl represent the amount of formazan detected in viable cells. 
3.2.2.7.3 Lactobacillus viability assay 
       The Lactobacillus viability assay is performed to assess the effect of chitosan NPs 
on L. crispatus growth using the established method47. Briefly, the bacteria density is 
adjusted to an OD670 of 0.06, corresponding to a 0.5 McFarland Standard or 108 CFU/ml48. L. 
crispatus is plated in a 96-well plate at a volume of 100 μl, and then incubated with 100 μl of 
1 mg/ml NP suspension under 37 °C. Commercially available 10 μg/ml of 
Penicillin-Streptomycin solution (Invitrogen, Carlsbad, CA, USA) is used as positive control. 
After 4 and 48 h, 20 μl of MTS reagent is added to each well and the bacterial viability is 
determined by a microplate reader by measurement of the absorbance at a wavelength of 490 
nm. The percent viability can be calculated using the above Equ. 3-3. 
3.2.2.8 Bioadhesion test 
       Fluorescein isothiocyanate (FITC)-labeled chitosan is synthesized based on the 
reaction between the isothiocyanate group of FITC and amino group of chitosan49, using the 
method previously described50. Porcine tissue is freshly obtained from the local abattoir 
(Fairview Farm Meat Co., Topeka, KS, USA) within 2 h of the death of the animal51. The 
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tissue is washed with normal saline, snap-frozen in liquid nitrogen, and kept at -80 ºC. When 
required, the tissue is thawed at 4 ºC then brought to room temperature gradually52 and cut 
into pieces of 8 cm length and 1 cm width. The outside of the vaginal tissue is stuck to a 
plastic strip by cyanoacrylate glue, which is resistant to water and harmless to the tissue as 
previously reported53. Then, the tissue-containing strip is immersed into a tube containing 
FITC labeled NPs (10 mg/ml) in 10 ml of VFS. The tube is put into a shaking water bath for 
30 min at 100 rpm, and then removed for analysis of the remaining fluorescence in the VFS54. 
The fluorescence of the VFS before and after the treatment is analyzed by a microplate reader 
at λex490 nm and λem520 nm. The percent mucoadhesion is calculated as follows: 
       
(%) 100I
I
F F
Mucoadhesion
F
 u        (3-4) 
       Where FI is the initial fluorescence and F is the remaining fluorescence of the VFS 
after the treatment54. 
3.2.2.9 Statistics analysis data  
       All experiments are performed in at least three independent assays. The results are 
given as mean ±standard error of the mean (SEM). Statistical comparisons of the results to 
control are made with independent sample t-tests or ANOVA. The level of significance is 
taken as p value < 0.05. 
3.3 Results and discussions 
3.3.1 Formation and physicochemical characterization of CS NPs 
       Upon addition of TPP, the NPs are formed through the gelation process. The results 
of the Box-Behnken design for EE% (Y1), average particle size (Y2), and polydispersity 
index (PI) are shown in Tab. 3-2.  
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Tab. 3-2 Box-Behenken experimental design of independent variables with measure 
responses 
Model X1 X2 X3 Y1 PI Y2 
−−0 -1 -1 0 4.47 0.307 174.1 
−0− -1 0 -1 2.07 0.316 183 
−0+ -1 0 1 1.23 0.436 209.1 
−+0 -1 1 0 3.11 0.227 168.5 
0−− 0 -1 -1 4.25 0.284 238 
0−+ 0 -1 1 0 0.272 228.2 
000 0 0 0 4.57 0.411 196 
000 0 0 0 5.09 0.226 188.2 
000 0 0 0 4.33 0.236 176.8 
0+− 0 1 -1 6.04 0.272 179.1 
0++ 0 1 1 2.98 0.319 277 
+−0 1 -1 0 2.42 0.248 231.3 
+0− 1 0 -1 6.07 0.249 204.5 
+0+ 1 0 1 3.98 0.306 217.8 
++0 1 1 0 7.33 0.428 250.1 
 
       The polynomial Equations for both response values are: 
Y1=4.66+1.12X1+1.04X2-1.28X3+1.58X1X2-0.31X1X3+0.30X2X3-0.16X12-0.18X22-1.17X32           
(3-5)   
Y2=187+21.13X1+0.37X2+15.94X3+6.1X1X2-3.2X1X3+26.93X2X3-3.99X12+22.99X22+20.59
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X32   (3-6) 
       Equ. 3-5 and 3-6 show the effect of the independent variables and their influences 
on the EE% and particle size. The coefficient of interaction terms show how the Y1 and Y2 
changed when the two independent variables changed simultaneously. The significance of 
these variables and their interactions are shown in Fig. 3-1.  
 
Fig. 3-1 Standardized pareto chart for Y1 (A) and Y2 (B). Pareto chart showing the 
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standardized effect of formulation variables and their interaction on Y1 and Y2. The X-axis 
shows the t ratio of the variables; bars extending pass the vertical line indicate values 
reaching statistical significance (α=0.05). 
       The values on the x-axis of the Pareto charts represent the standardized effects, 
which are in fact the ratio of estimate and the standard error of the factor effect (t value)55. 
The obtained t value is compared to a tabulated critical t value, which is determined at 
α=0.05 forresidual degrees of freedom (df), where df=5 from ANOVA (Tab. 3-3)56. 
Tab. 3-3 ANOVA analysis for both responses. 
Response Source DF SS MS F ratio P value 
Y1 Model 9 47.376 5.26 4.77 0.049 
Error 5 5.50 1.10   
Total 14 52.88    
Y2 Model 9 12147.75 1349.75 3.33 0.099 
 Error 5 2025.05 405.01   
Total 14 14172.80    
DF: degree of freedom, SS: sum of square, MS: mean sum of square, F ratio: Model 
MS/error MS 
 
The factors whose length passed the vertical line (tcritical=2.571 at P<0.05) indicates 
significance on the response value57. According to Fig. 3-1, X3, X1, X1X2, and X2 contributed 
substantially to EE% (Fig. 3-1 A), while X1 and X2X3 contributed to size (Fig. 3-1 B). 
Chitosan is used in these nano-formulations as polymeric matrix required to entrap the drug 
and to allow controlled drug release. The concentration of chitosan (X1) is found to increase 
the EE%. By increasing the amount of polymeric matrix (chitosan), more TFV could interact 
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with the chitosan through electrostatic forces. TPP is the cross-linking agent. By increasing 
the weight ratio of TPP/chitosan (X2), more chitosan molecules, which contain several drug 
molecules, can participate in the gelation process and form NPs so that more drug can be 
entrapped into the particles. The interaction factor X1X2 is also positively related to the EE% 
as a result of the above phenomena. The ratio of TPP/chitosan and TFV/chitosan is chosen 
according to the Nitrogen to Phosphate or N/P ratio previously described58. Briefly, the molar 
ratio of the amino/phosphate group (N/P ratio) in the solution should be larger than 1:1. A 
high EE% occurred when the molar ratio of the amino group of chitosan to the phosphate 
group of drug is 8:1. These values agrees with the results obtained from the BBD design 
where the ratio of drug/chitosan (X3) shows a negative effect on the EE%, which meant that 
the higher the relative amount of drug to polymer in the solution, the lower the percentage of 
the total drug that can be entrapped in the NPs. 
       According to Fig. 3-1 B, the concentration of polymer (X1) in this study has a 
positive effect on the NP size, which agrees with published results59 that larger sized NPs are 
obtained with higher concentrations of chitosan. However, the mechanism by which X2X3 
contributed to size increase is not clear, perhaps because TPP and TFV (both with phosphate 
groups) competitively interacted with the same chemical group of chitosan. Therefore, X2X3 
interaction might affect the cross-linking efficiency leading loosely packed polymeric chain 
inside the NPs with increased particle size. 
       At a medium amount of chitosan the TPP and drug mixture is required to achieve a 
higher EE% and lower size. Base on the interaction plot shows in Fig. 3-2 and Equ. 3-5 and 
3-6, the optimal formulation, which exhibited the highest EE% (5.83%±0.88%) and lowest 
particle size (207.97±19.07 nm), is selected through the mathematical optimization process, 
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where X1, X2, and X3 are 0.66, 0.67, and -0.69.  
 
Fig. 3-2 Prediction profiler and desirability plot showing the effect of formulation variables 
on EE% (Y1) and size (Y2). 
       A check point analysis base on Equ. 3-5 and 3-6 is performed to confirm; the 
analysis is shown in Tab. 3-4.  
Tab. 3-4. Checkpoint experiments comparing measured predicted value (n=3) 
Ru
n 
no. 
X1 X2 
X
3 
Measur
ed Y1 
Pre
dic
ted 
Y1 
Error
% of 
Y 1 
P 
valu
e of 
Y1 
Measure
d Y2 
Predic
ted Y2 
Error
% of 
Y2 
P 
Valu
e of 
Y2 
C1 -0.5 
-0.
5 
-0
.5 
5.55 
(±1.82) 
4.2 30.9 0.34 
166.23 
(±16.05) 
185.6 -10.4 0.17 
C2 0.5 0.5 
0.
5 
3.18 
(±1.44) 
5.1 -42.7 0.15 
266.33 
(±85.84) 
223.0 20.7 0.47 
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C3 0.66 
0.6
7 
-0
.7 
5.83 
(±0.88) 
6.9 -16.4 0.15 
207.97 
(±19.07) 
200.3 3.8 0.56 
 
       Three points are selected: two random points out of the 15 runs of the experiment, 
and the above theoretical and optimal point. Though the Error % on the EE% is large (which 
might resulte from the variability in the UV spectroscopy absorbance reader), the differences 
between measured and predicted values are not found to be statistically significant (p > 0.05); 
thus, it can be concluded that these Equations fit the data satisfactorily and are valid for  
3.3.2 predicting the EE% and the particle size. 
       At a higher pH, more particles are formed compared to a lower pH because the 
proportion of the protonated amino groups in chitosan is pH dependent. Chitosan has weak 
basic amino groups that are protonated in acidic medium. TPP with a negative charge could 
interact strongly with positively charged chitosan in such a low pH environment60. 
       However, in optimal conditions of the BBD design, the EE% of TFV is quite low 
(5.83%), although the preparation is performed at a pH 6.5. To improve the EE%, a mixture 
of ethanol and water is used as a solvent for chitosan. The effects of ethanol concentration on 
the EE% and the size of NPs are shown in Fig. 3-3.  
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Fig. 3-3 EE% (A) and size (B) of NPs that are formed in water and in 50% (v/v) ethanol. 
: NPs formed under the conditions from exhibiting the highest EE% among the 15 run 
(X1=1, X2=1, X3=0); : NPs formed under the optimal condition (X1=0.66, X2=0.67, 
X3=-0.69) (n=3). * P<0.05 vs Water, **P<0.01 vs Water 
       The predicted water solubility of TFV is 1.87 mg/ml and Log P is -1.661; thus, the 
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observed low EE% may be explained by the relatively high hydrophilicity of the drug. It has 
been reported that polysaccharide-based drug-delivery systems usually have a low EE% and 
drug loading for water-soluble drugs with low molecular weight62. TFV could not dissolve in 
ethanol, and the addition of ethanol reduced the amount of required water. As a result, the 
solubility of TFV in ethanol is lower than that in water alone. Therefore, the drug could not 
diffuse out in massive amounts during the NP preparation, leading to a higher EE%63. Indeed, 
the EE% with ethanol on the optimal condition is 20.05±3.27% (n=3), which is almost three 
fold higher than that of water alone. 
       However, the use of ethanol also increased the particle size from 207.97±19.07 nm 
to 580.60±98.71 nm. The size increase might be explained by the Kelvin Equation (Equ. 
3-7):  
       0
2
ln m
Vp
p rRT
J                                               (3-7)  
       Where p is the actual vapor pressure of the liquid, p0 is the saturated vapor pressure, 
γ is the surface tension, Vm is the molar volume, R is the universal gas constant, r is the radius 
of the droplet, and T is temperature. Rewriting Equ. 3-8 gives: 
       0
2
ln
mVr
p
RT
p
J                                                (3-8) 
       The surface tension of ethanol (22.8 mN/m) is less than that of water (72.8 mN/m)64; 
thus, ethanol can significantly decrease the surface tension of the chitosan solution. 
According to Equ. 3-8, the radiuses of the droplets (r) decrease with the decrease in the 
surface tension when the other Equation parameters are fixed, which means that ethanol can 
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lead to smaller droplets. 
       Even if we assume that γ effect is negligible, another important parameter that 
describes droplet deformation is the Weber number (We): 
       2
G R
We
K
J                                                 (3-9) 
       Where G is the share stress, K is the viscosity, R is the radius of the droplets, andJ is 
the interfacial tension65. Equ. 3-10 can be rewritten as: 
       
2We
R
G
J
K                                                 (3-10) 
       The radius of the droplets decreases with the increase of K . At 25 °C, the viscosity 
of water is 0.894 cP, while the viscosity of ethanol is 1.074 cP66, which means that the 
ethanol addition also leads to smaller droplets. 
       The initial smaller particles, produced under the influence of either low surface 
tension or low viscosity induced by ethanol, will undergo Brownian motion and particle 
collision leading to particle growth. In fact, the growth of aggregates can be simulated by 
making simple assumptions concerning the transport of particles to the growing agglomerate, 
and the events that occur when primary particles collide with the growing aggregate. The 
relationship between mass and final size of the NPs can be defined by a mass-fractal 
aggregation Equation: 
        
1/ dfR ND                                                (3-11) 
       Where α is the Lacunarity constant, R is the aggregate overall size, N is the number 
of primary particles in an aggregate, and df is the mass-fractal dimension which ranges from 
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1 to 3 in a 3-dimensional space. The colliding particles can probe the surface of the growing 
aggregate, or become “trapped”, by high coordination number regions of the aggregate. 
According to Equ. 3-11, the larger number of colliding droplets leads to the growth of larger 
droplets, which agrees with the result that the size of the final NPs cured in ethanol solution 
is relatively larger. Fig. 3-4 shows the mean size distribution of particles formed in water (Fig. 
3-4. A) and 50% (v/v) ethanol (Fig. 3-4. B). These size analyses data are consistent with the 
TEM data (Fig. 3-5). 
 
 
Fig. 3-4. Particle size distributions by intensity of chitosan NPs formed in water (A) and in 
50% (v/v) ethanol (B). 
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Fig. 3-5 Transmission electron microscopy (TEM) of chitosan NPs prepared using water (A) 
and 50% (v/v) ethanol (B) as the preparation media. 
3.3.3 In vitro release study 
        Drug release from solid dosage form has been described by kinetic models such as 
zero-order, first order, Higuchi model, Peppas model, and Hixon-Crowell67. The release data 
is fitted to zero-order, first order, and the Higuchi model to propose the release mechanism68. 
Tab. 3-5 shows the formulation and characteristic of NPs used in the release study.  
Tab. 3-5 Physical-chemical properties of NPs used in drug release and cytotoxicity studies. 
(n=6) 
Size Formulation Average 
particle 
size (nm) 
Zeta 
potential 
(mV) 
EE % Drug 
loading % 
(w/w) 
X1 X2 X3 Preparati
on media 
Low -1 0 -1 water 182.36 
(±15.83) 
46.4 
(±1.22) 
2.1 
(±0.6) 
0.21 
(±0.06) 
Mediu 0.66 0.67 -0.69 water 281.67 53.07 6.9 0.33 
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m (±25.62) (±0.56) (±0.7) (±0.05) 
High 0.66 0.67 -0.69 ethanol/
water 1/1 
(v/v) 
602.43 
(±48.96) 
55.23 
(±2.29) 
23.5 
(±1.2) 
1.14 
(±0.06) 
       The suspensions are stable, with zeta potential being as high as 45-55mV, which is 
also close to the results reported in the previous published literature34, 69. The positive charge 
of NPs is due to the amino groups on the surface of the NPs. The drug release profiles of 
chitosan NPs are shown in Fig. 3-6.  
 
Fig. 3-6. In vitro release profiles of chitosan NPs with small, medium and large size (n=3). 
       It is noteworthy that small-sized NPs shows an initial burst release phase within the 
first 8 h. Since it is well known that in most of the drug release conditions for the particles, a 
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higher drug loading level generally leads to a higher drug release rate because of the 
enhanced diffusion driving force of the concentration gradient63. However, in this study the 
burst release occurred possibly due to the small size of the NPs. As the particle diameter is 
reduced, the specific surface area increased, while the path length to the surface of the drug 
decreased70. It is thus more likely for a drug to be released from the NPs. Medium and 
large-sized NPs provided a controlled drug release without an obvious burst release. Drug 
release from medium-sized NPs fit well with the Higuchi model67: 
       Q=7.15t1/2-4.04          (r2=0.991)                              (3-12) 
       Where Q is the percent of drug released in time t. The high-sized NPs fit with the 
first-order release model67: 
       ln(100-Q)=-0.0078t+4.5   (r2=0.999):                             (3-13) 
       Both of medium-sized and large-sized NPs could be considered as promising drug 
nanocarriers for controlled release of the microbicide. The size of NPs appears to be a major 
factor affecting the drug release rate. 
       The average daily release of TFV from chitosan NPs is 14% (medium) and 12% 
(large). As the drug loading of the two kinds of particles is 0.33% (w/w) and 1.14% (w/w) 
(Tab. 3-5), 1 mg of NPs could release 0.5×10-3 mg and 1.4×10-3 mg of drug every 24 h. 
Women of reproductive age produce fluid at a rate of approximately 6 ml/day71, while the 
EC50 of TFV is about 0.5 μM72, which means that about 1.7 g of medium size chitosan NPs, 
or 0.6 g large-size chitosan NPs, would be able to provide the daily requirement of TFV for 
an adult woman patient. This is feasible considering that the average vaginal suppository that 
could be measured as an additional vehicle had a weight of 5 grams. 
3.3.4 Cytotoxicity studies 
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3.3.4.1 LDH release study 
       Lactate dehydrogenase (LDH) and MTS tests are utilized to evaluate the effect of 
chitosan NPs on both cellular viability and membrane integrity. The LDH from cells with 
damaged membranes is determined by measuring the fluorescent signal. NPs used in this 
study are the same as shown in Tab. 3-5, but without drug loading. After incubation with 
chitosan NPs for 4 and 48 h, only minimal LDH release from vaginal epithelial cells is 
observed. As shown in Fig. 3-7, the extent of the release of LDH from the cells incubated 
with NPs is 10% higher than that of media. 
 
Fig. 3-7. LDH release of vaginal epithelial cells treated by chitosan NPs with different sizes 
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for 4 h (A) and 48 h (B), (n=3). * P<0.05 vs Media, **P<0.01 vs Media 
3.3.4.2 Cell viability study 
       The MTS tetrazolium compound is able to be bioreduced by living cells into a 
colored formazan product that is soluble in the cell culture media. Thus, after the incubation, 
the number of living cells could be determined by the absorbance of the formazan product of 
MTS. The viability of cells, which is higher than 80%, is shown in Fig. 3-8. For some in the 
sample, the cell viability is even higher than 100% in comparison with the media control, 
which may be due to the differences of the number of cells in each well. 
 
Fig. 3-8. Percent viability of vaginal epithelial cells treated by chitosan NPs with different 
sizes for 4 h (A) and 48 h (B), (n=3). * P<0.05 vs Media, **P<0.01 vs Media 
 45
       In both of the assays, no statistical difference is observed by the t-test between 
media control and NPs with different sizes, which means that the chitosan NPs are not 
harmful to the cells and the size has no effect on cytotoxicity. 
3.3.4.3 Effects on Viability of Lactobacillus Crispatus 
       Lactobacillus, which is a predominant normal vaginal floral species, is used as 
model bacteria since it is able to produce hydrogen peroxide (H2O2)10. It is critical that any 
microbicide formulation won’t disturb normal vagina flora so that they can maintain a low 
pH environment and secrete H2O2, which provides a natural barrier for HIV transmission48. 
       As shows in Fig. 3-9, after incubation for 4 and 48 h, there is no statistical difference 
between the media control and the chitosan NPs, which suggests that these NPs are not 
harmful to the cells and the size has no effect on cytotoxicity. 
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Fig. 3-9. Percent viability of Lactobacillus cripatus treated by chitosan NPs with different 
sizes for 4 h (A) and 48 h (B), (n=3). * P<0.05 vs Media, **P<0.01 vs Media 
3.3.5 Mucoadhesion studies 
       Porcine vaginal tissue is used for this study because vaginal mucosa is a realistic and 
reproducible system to assess the therapeutic potential of new agents in humans73. After 
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fluorescence tagging, the average diameter of small, medium, and large particles is 
188.7±43.3 nm, 273.5±53.1 nm, and 900.2±118.4 nm, respectively. For large-sized NPs, the 
difference in size may be due to the ethanol use. The performance of most drugs could be 
improved by using bioadhesive carriers, which provide prolonged contact time between the 
polymeric system and mucous layer surface71, and a controlled drug release. Chitosan has a 
well-known bioadhesive property by establishing the electrostatic interactions with sialic 
groups of mucins in the mucus layer74, which is on the surface of the vaginal tissue. 
Moreover, it is also demonstrated that chitosan can enhance the absorption of hydrophilic 
molecules by promoting a structural reorganization of the tight junction-associated proteins75. 
       The contribution of particle size to the mucoadhesion % of chitosan NPs is shown in 
Fig. 3-10. There is no statistical difference between low and medium-sized NPs (P=0.32); 
however, the mucoadhesion % of large-sized NPs is halved (P value between low and large 
size NPs is 0.003). 
 
Fig. 3-10. Percent mucoadhesion of chitosan particles with different sizes on porcine vaginal 
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tissue. After fluorescence labeling, the mean diameters of small, medium, and large particles 
are 188.7±43.3 nm, 273.5±53.1 nm, and 900.2±118.4 nm, respectively for n=3. 
       Since the mucoadhesive properties of the NPs are due to the electrostatic attraction 
between chitosan on the surface of the NPs and the sialic acid group of mucin, the total 
specific surface area is the decisive factor of the mucoadhesion. For small particles, more 
chitosan molecules have a chance to contact the mucous layer. Thus, the mucoadhesive 
property of small chitosan NPs is improved. To achieve a desired dosage, both the EE% and 
mucoadhesion % (MA%) should be considered to efficiently identify the ultimate 
formulation process. Assuming that for all the three kinds of NPs, drug EE% remains 
unchanged after fluorescence tagging, the mass fraction of EE% × MA% is found to be 
0.26%, 0.99%, and 1.71%, respectively, using the approach in the previous report76. Though 
the percent mucoadhesion of large-sized NPs is lower than that of low and medium-sized 
particles, the mass fractions are higher than that of the other two kinds of particles, which 
indicates that large-sized chitosan NPs are ultimately the most promising vehicle for 
preparing chitosan based vaginal or topical microbicide delivery. 
3.4 Conclusion 
       In this work, reported for the first time, microbicide loaded chitosan NPs are 
prepared by ionic gelation. The EE% of TFV, which is used as a model microbicide, could be 
improved significantly by using an ethanol solution as a solvent of chitosan. However the use 
of ethanol also increases the particle size. The in vitro release, cytotoxicity assays, and 
mucoadhesive studies suggests that relatively large chitosan NPs have the potential to be a 
controlled release, safe, and bioadhesive microbicide delivery system. These properties make 
chitosan NPs good candidates for the topical vaginal microbicide delivery system for further 
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study related to the quest of the prevention of HIV transmission. 
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CHAPTER 4 
COMPARATIVE BIOPHYSICAL PROPERTIES OF TENOFOVIR LOADED THIOLATED 
AND NON-THIOLATED CHITOSAN NANOPARTICLES INTENDED FOR HIV 
PREVENTION 
4.1 Rationale 
       Numerous polymers and hydro gel have been used to prolong the residence time at 
the site of application. Among which, chitosan (CS) is a promising candidate because of its 
favorable biological properties such as non-toxicity, biocompatibility, and biodegradability77. 
Compared to unmodified CS, it has been shown that the thiolation of CS, by the covalent 
attachment of thioglycolic acid (TGA), leads to a strongly improved mucoadhesion78. 
Chitosan thioglycolic acid conjugation (TCS) display thiol bearing side chains that mimic the 
natural mechanism of secreted mucus glycoproteins29. Based on thiol/disulfide exchange 
reactions, and/or a simple oxidation process, disulfide bonds are formed between polymers 
and cysteine-rich subdomains of mucus glycoproteins so that the polymers can covalently 
anchor in the mucus layer30. 
       We have recently engineered TFV loaded CS NPs79 to increase drug retention into 
the topical route. In order to further maximize the microbicide mucoadhesion, TCS is used 
here instead of native CS during the preparation of NPs. This study is thus designed to test 
the hypothesis that anti-HIV microbicide (TFV) loaded TCS NPs exhibit superior biophysical 
properties for mucoadhesion to the vaginal epithelium compared to those of native CS NPs 
and gel formulations. TCS is chosen as a matrix of the drug carrier, and sodium 
tripolyphosphate (TPP) worked as a cross-linking agent. NPs are prepared on the basis of the 
ionic gelation of TCS with TPP anions80.  
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4.2 Materials and methods 
4.2.1 Materials 
       Chitosan (CS) (molecular weight of 50঎190 KDa), sodium triphosphate pentabasic 
(TPP), DL-dithiothreitol (DDT),and lysozyme (activity: 50 units/mL at 5μg/mL)from 
chicken egg white are purchased from Sigma Aldrich (St. Louis, MO, USA). Tenofovir (TFV) 
is purchased from Zhongshuo Pharmaceutical Co. Ltd. (Beijing, China). Acetic acid and 
methanol are supplied by Fisher Scientific (Pittsburgh, PA, USA). 
Fluorescein-5-isothiocyanate (FITC) is purchased from Invitrogen (Carlsbad, CA, USA). 
       The human vaginal epithelial cell line VK2/E6E7, human endo cervical epithelial 
cell line End/E6E7 and Lactobacillus crispatus (ATCC Number 33197) are purchased from 
American Type Culture Collection (ATCC, Boston, Massachusetts, USA). The 
Keratinocytes–SFM serum-free medium is from GIBCO Invitrogen (Carlsbad, California, 
USA); the medium composition is modified to reach the desired calcium concentration by 
adding CaCl2 (0.4 mM) 155 μl/100ml medium, recombinant epidermal growth factor (0.1 
ng/ml), (2.69 μl/100 ml), and bovine pituitary extract (400 μL/100 mL).L. crispatus is grown 
in an ATCC medium 416 Lactobacilli MRS broth (BD, Franklin Lakes, NJ, USA). AQueous 
nonradioactive cell proliferation assay 
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazoliu
m, inner salt; MTS], and lactate dehydrogenase (LDH) cell cytotoxicity kit 
(CytoTox-ONETM), are purchased from Promega (Madison, WI, USA). All other chemicals 
used in this study are of analytical grade and used as received without further purification. 
4.2.2 Methods 
4.2.2.1 Synthesis of chitosan-thioglycolic acid conjugates (TCS) 
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       Chitosan-thioglycolic acid conjugates or thiolated chitosan (TCS) is synthesized 
using a previously described method81. Briefly, 100 mg of chitosan is dissolved in 10 ml of 
0.1 M HCl to obtain a 1% w/v solution of chitosan hydrochloride. Then 100 mg (1.09 mmol) 
of TGA is added. After TGA is completely dissolved in the chitosan hydrochloride solution, 
10 mg (0.05 mmol) of EDC and 15 mg (0.13 mmol) NHS is added. The pH is adjusted to 5 
and the reaction mixture is incubated for 3 h at room temperature under constant stirring. 
The control samples are without EDC and NHS also prepared and analyzed. 
       The reaction mixture subsequently, undergoes dialysis for 3 days at 10°C in the dark 
against 1L of 5 mM HCl to isolate the pure chitosan conjugates and to eliminate unbound 
TGA, then against the same medium but containing 1% w/v NaCl, in order to reduce the 
ionic interactions between chitosan and the sulfhydryl compound.  
4.2.2.2 Proton nuclear magnetic resonance (1H-NMR) spectroscopy analysis of TCS 
       In order to confirm the effective conjugation between CS and TGA, proton (1H) 
NMR spectroscopy analysis is performed. The samples are dissolved in deuterium oxide 
(D2O). The spectra are observed on a Varian (Palo Alto, CA, USA) 400MHz spectrometer 
with a Varian two channel probe. Vnmrj 2.2 (Palo Alto, CA, USA) is used to process the 
experimental data. Typically, the spectra are acquired with relaxation delay of 2 sec and the 
number of scans is 2048. The concentration of each 500 μl sample is 4 mg/ml.  
4.2.2.3 Preparation of tenofovir (TFV) loaded TCS based NPs 
       TCS is hydrated in 2 ml of purified water for 1 h, and then dissolved in 10 ml 1% 
acetic acid at concentrations of0.1%, 0.2% and 0.3%(w/v%). The method of preparation is 
adapted from the method described by Fernandez-Urrusuno et al.43. Briefly, TPP is dissolved 
in 1 ml purified water. The weight ratio of TPP/TCS is 0.1, 0.2 and 0.3respectively. The TFV 
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is dissolved in 0.5 M NaOH solution. The weight ratio of TFV/TCS is 0.1, 0.2 and 
0.3respectively. The concentrations of TCS, TPP, and TFV solution are shown in Tab. 4-1.  
Tab. 4-1 Independent Variables and their levels in Box-Behnken Design 
Independent variables Low Medium High 
X1= concentration of TCS (w/v %) 
X2= TPP/TCS weight ratio 
X3= drug/TCS weight ratio 
Coded values 
0.1 
0.1 
0.1 
-1 
0.2 
0.2 
0.2 
0 
0.3 
0.3 
0.3 
1 
Dependent variables  
Y1= encapsulation efficiency (EE %) 
Y2= particle mean diameter (nm) 
 
       The drug solution is added to the CS solution and followed by the addition of the 
TPP solution under magnetic stirring at room temperature. The system is then stirred for 10 
min at room temperature. The NP suspension is formed spontaneously by ionic gelation. 
       NPs are separated by centrifugation (Beckman L8-70 M Ultracentrifuge, Brea, CA, 
USA) at 12,000 rpm(g force 19560 xg), 20 °C for 40 min. The supernatant, which is clear 
and translucent, is used to determine the drug EE%; the cake is washed three times with 
deionized water, freeze-dried (Labconco Corporation, Kansas City, MO, USA) and stored at 
4°C until use. 
        The preparation of FITC-labeled CS and TCS is based on the reaction between the 
isothiocyanate groups of FITC and the amino groups of CS49, as previously described50. The 
FITC-labeled CS NPs are prepared also by ionic gelation (as described above), characterized, 
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and used for mucoadhesion and uptake studies as shown below. 
4.2.2.4 Determination of drug encapsulation efficiency (EE%) 
       After centrifugation, the supernatant is used to determine the percent drug EE%. The 
amount of unencapsulated (or free) drug in the supernatant is measured by UV spectrometer 
(Spectronic Genesys 10 Bio, Thermo Electron Corperation, WI, USA) at a wavelength of 259 
nm. The content of TFV is calculated using the following Equ. 4-1: 
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4.2.2.5 Size and size distribution analysis 
       The particle mean diameter and polydispersity index (PDI) in water medium are 
determined by dynamic light scattering (Zetasizer Nano ZS Malvern Instruments Ltd, 
Worcestershire, UK) base on the intensity of the processed light signal82. The particle mean 
diameter is represented as Z-average diameter following the cumulant model. The PDI is 
given by the following Equ. 4-2: 
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       Where K1 is an effective mean diffusion coefficient and K2 is the relative width of 
the size distribution if normalized by K182.
       The measurements are taken at the temperature of 25°C. Each measurement is 
repeated three times and an average value is reported. A sample with a PDI < 0.05 is 
considered monodispersed according to the National Institute Standard1. 
4.2.2.6 Morphological analysis 
       The morphology of the NPs is examined by the scanning electron microscope (SEM) 
and transmission electron microscopy (TEM). To obtain the specimens, after freeze-drying, 
NPs are mounted to aluminum stubs with conductive tape, and sputter coated with 20 nm of 
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gold–palladium alloy. The NPs are visualized under a Philips SEM 515 microscope 
(Philips/FEI, Eindhoven, NL). For TEM, 8 μL of the particle suspension are placed on a 
copper grid with a carbon support film, allowed to equilibrate for 5 min, and then air dried. 
The grids are viewed under a transmission electron microscope (Philips CM12 STEM, Philips 
Electronic Instruments, Inc., Mahwa, NJ).Digital images are acquired with the large format 
(II Megapixel), retractable, and fiber-optical coupled CCD camera SC100 ORIUS© CCD 
camera. 
4.2.2.7 In vitro TFV release profile 
       The in vitro release of NPs is compared with hydroxyethyl cellulose (HEC) gel 
containing TFV, with TFV powder used as a control. Ten milligrams of NPs, HEC gel 
containing 1% of TFV and 0.2 mg of TFV powder are suspended, respectively, in the 
Spectra/Por cellulose ester membrane dialysis bag (Spectra/Por Float-A-Lyzer G2, MWCO 
3.5-5 KD, Spectrum Laboratories Inc. Rancho Dominguze, CA, USA), and thenimmersed in 
a tube containing 20 ml vagina fluid simulant (VFS) at pH 4.2. The VFS is prepared 
according to previous reports45. The tubes are kept in a thermostatically controlled shaking 
water bath (BS-06, Lab Companion, Seoul, Korea) that is maintained at 37ºC and 60 rpm. At 
predetermined time intervals, all the buffer solution (20 ml) outside the dialysis bag is 
removed and replaced by fresh buffer solution to maintain a sink condition. The 
concentration of drug in the buffer solution is determined by a UV spectrometer at 259 nm. 
Each experiment is run in triplicate together with a blank NP control. One hundred percent 
drug release is obtained from complete enzymatic digestion of NPs using lysozyme after 120 
h using the method of Don et al.83. TCS NPs obtained under the optimal conditions are used 
in this study compared with CS NPs prepared at the same condition. 
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       The drug release data are fitted to kinetic models below (Equ. 4-3 to 4-5), 
respectively, related to zero-order, first-order, and Higuchi model to elucidate the release 
mechanism84. 
       For zero-order kinetics: 
       Q=kot,                                      (4-3) 
       Where Q represents the percent of drug released in time t, and ko is the apparent 
release rate constant or zero-order release constant. 
       For first-order kinetics: 
       ln(1-Q)=–k1t                                 (4-4)
       Where Q represents the percent of drug released in time t, and k1 is the first-order 
release constant. 
       For Higuchi model: 
       Q=kHt½                                      (4-5) 
       Where Q represents the percent of drug released in time t, and kH is the Higuchi 
dissolution constant. 
4.2.2.8 Cell cultures 
       Two cell lines are used in this study: human vaginal keratinocyte cell line 
VK2/E6E7 and human endocervical epithelial cell line End/E6E7. Both cell lines are grown 
in the Keratinocytes-SFM medium, which is with 10% (v/v) fetal bovine serum (FBS) and 1% 
penicillin/streptomycin. Cells are cultured at 37°C in a humidified 5% CO2 atmosphere and 
sub-cultured prior to confluence using trypsin. 
4.2.2.8.1 LDH release studies 
       To measure the lactate dehydrogenase (LDH) release, cells are seeded in 96-well 
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plate. After 80% confluence is reached the cells are incubated with 100 μl media containing 1 
mg/ml blank or TFV loaded CS or TCS NPs, or 200 μg/ml TFV in each well. A media 
without NPs is used as a negative control, and 1% Triton-100 X is used as a positive control. 
The background fluorescence that might be present due to the media only, is kept by adding 
NP suspension to the cell-free wells. The plate is incubated at 37°C for 4, 24, and 48 h and 
then equilibrated to 22 °C. At different time intervals, 100 μl of CytoTox-ONE™ Reagent 
(Promega, Madison, WI, USA) is added to each well and shaken for 30 s. The plate is 
incubated at 22 °C for 10 min and then 50 μl of stop solution is added. The fluorescence is 
determined by a microplate reader at λex 560 nm and λem 590.The percent LDH released by 
the cell membrane is calculated using Equ. 4-6: 
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       Where FExperimental, FBackground and FPositive represent the fluorescence intensity of 
NPs-treated, background (without cells), and positive control (cells treated with 1% 
Triton-100 X) wells, respectively. 
4.2.2.8.2 Cell viability assays
       The cell viability is determined by adding MTS and then checking the amount of a 
colored formazan product that is bioreduced from MTS by cells. Cells are seeded and 
incubated with1 mg/ml blank or TFV loaded CS or TCS NPs, or 200 μg/ml TFV under the 
same condition as above and by following the manufacturing protocol. At different intervals 
(4, 24, and 48 h), the particle suspension is removed and substituted with fresh medium. 
Twenty microliters of CellTiter 96®Aqueous One Solution Reagent (Promega, Madison, WI, 
USA) is added to each well and incubated at 37°C for 4h. The absorbance is recorded at a 
wavelength of 490 nm. The cell viability is expressed using Equ. 4-7: 
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       Where ATest and AControl represent the absorbance related to the amount of formazan 
detected in viable cells in wells treated with NPs and not treated with NPs, respectively. 
       The lactobacillus viability assay is performed in order to assess the effect of CS NPs 
on L. crispatus growth using the established method47. Briefly, the bacteria density is 
adjusted to an OD670 of 0.06, corresponding to a 0.5 McFarland Standard or 108 CFU/ml48a. L.
crispatus is plated in a 96-well plate at a volume of 100 μl and then incubated with 100 μl of 
medium containing 1 mg/ml blank or TFV loaded CS or TCS NPs, or 200 μg/ml TFV at 
37 °C.A commercially available 10 μg/ml of Penicillin-Streptomycin solution (Invitrogen, 
Carlsbad, CA, USA) is used as a positive control. After 4, 24, and 48 h, 20 μl of MTS reagent 
are added to each well, and the bacterial viability is determined by measurement of the 
absorbance at a wavelength of 490 nm by a microplate reader. The percent viability can be 
calculated using the above Equ. 4-7. After 48 h, the bacterial is imaged with a microscope 
(Nikon Instruments, Inc. Melville, NY) at a magnification of 1000. 
4.2.2.8.3 Cellular uptake studies 
       Cellular uptake studies are performed using a microplate reader and a confocal 
microscope as previously described85. The cells (1 x 104) are seeded in 96-well plates. After 
80% confluence is reached, the cells are incubated with FITC labeled CS and TCS NPs 
suspension (500 μg/ml in the media). Cells treated with media only are used as background. 
The control is determined by adding NP suspension in a row of wells without cells. After 4, 
24, and 48 h, the suspension in the test wells is removed and the cells are washed three times 
using a phosphate buffer saline (PBS, pH = 7.4) solution. One percent of Triton-100 X is 
added for cells lysis, the fluorescence is measured using a microplate reader. The cellular 
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uptake efficiency is calculated using Equ. 4-8: 
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       Where Fcell and Fcontrol represent the fluorescence intensity related to the amount of 
particles up taken in the cells in test wells and in the control wells, respectively. 
4.2.2.8.4 Flow cytometry analysis 
       Both VK2/E6E7 and End/E6E7 cell lines are cultured in the T-25 culture flask till 80% 
confluence. FITC labeled CS and TCS NPs (500 μg/ml) are incubated with cells for 48 h. 
Cells treated with media only are used as a negative control. The cells are washed three times 
with PBS and harvested using 5 ml of trypsin for 5 min, then diluted with an equal volume of 
FBS. Finally, the number of cells containing FITC labeled NPs is measured using the BD 
LSR II Flow Cytometer (BD Biosciences 2350, Qume Drive San Jose, CA). 
4.2.2.8.5 Assessment of uptake using fluorescence microscopy 
       Both VK2/E6E7 and End/E6E7 cells are seeded on the 96-well plate at a 
concentration of 2 ×105cells/ml. After 48h incubation at 37°C, the cells are treated with FITC 
labeled CS and TCS NPs suspension (1 mg/ml in the media) and incubated for another48 h. 
Then the suspension in the test wells is removed and the cells are washed twice using a PBS 
solution (pH = 7.4). Cells treated with media are used as control. Subsequently, 100 μl of 
Hoechst 33342, a permeable DNA dye, prepared in PBS solution (10ug/ml) are added and the 
cells are incubated at room temperature for 20 min86. Then the cells are imaged with a 
fluorescence microscope (Nikon Instruments, Inc. Melville, NY) at a magnification of 400. 
DAPIand FITC filters are used to observe the nucleus (blue) and the NPs (green), 
respectively. The images processing is performed with Adobe Photoshop CS software (Adobe 
Systems, San Jose, CA, USA) 
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4.2.2.8.6 Cellular uptake inhibition study 
       Cytoskeleton reorganization is prevented by incubating the cells with cytochalasin D 
(10μg/mL) for 30 min followed by application of NP complexes. Macropinocytosis is 
promoted through treatment with phorbolmyristate acetate (PMA, 1 μM) for 30 min prior to 
addition of the complexes. Clathrin dependent endocytosis is disturbed by co-treatment with 
chlorpromazine (10μg/mL), following a 30 min pre-incubation at the same concentration. To 
perturb caveolin-mediated pathways, cells are pre-treated with genistein (100 μg/mL) for 30 
min. In all cases, the treatment of the cells with CS and TCS NPs is done in the presence of 
the respective NPs at the same concentration as used for the pre-treatment. Following 
treatment under these various conditions, cells are harvested after 24 h and analyzed as 
described above87. 
4.2.2.9 Mucoadhesion study 
       Fresh porcine vaginal tissues are obtained from the local abattoir (Fairview Farm 
Meat Co., Topeka, KS, USA).These tissues are washed using normal saline, snap frozen in 
liquid nitrogen, and then stored at -80°C. Before the experiment, the frozen tissue is thawed 
in normal saline at 37°C for 3 min. 
       The bioadhesive property of the NPs is determined, as described by RangaRao and 
Albrecht88, for the comparison of CS and TCS NPs using the infusion and immersion method. 
Porcine vaginal tissues are cut into strips of 8 cm long and 1 cm wide and then mounted on 
plastic strips of the same width using cyanoacrylate glue53. In the infusion method, each strip 
is put into a tube that is placed in a water bath of37°C at an angle of 45°. An equilibration 
period of 5 min with VFS is allowed before administering the particles to humidify the 
mucosa. The mucosa are then continuously rinsed with 10 ml VFS, which contained 10, 20, 
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and 30 mg of FITC labeled NPs. A constant flow rate of 1 ml/min is provided by using an 
infusion set. The fluid is collected, and the fluorescence of each fluid, before and after the 
treatment, is analyzed by a DTX 800 multimode microplate reader (Beckman Coulter, Brea, 
CA, USA) at λex490 nm and λem520 nm. The percent mucoadhesion (MA%) is calculated 
with Equ. 4-9: 
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       Where FInitial represents the initial fluorescence, and F represents the fluorescence 
after the treatment54. 
       The surface of the tissue is cleaned carefully, the tissue is cut into small cubes, 
embedded into Histoprep, frozen by using liquid nitrogen, and then sectioned vertically using 
a cryostat microtome. The skin sections (5 mm) are mounted on glass slides and visualized 
through a fluorescence microscopy without any additional staining or treatment89. 
Using the immersion method, the effects of time on bioadhesion are determined as follows: 
predetermined FITC labeled TCS NPs are suspended in VFS; the plastic strips with tissue are 
immersed into tubes containing 10 ml of VFS suspension; the tubes are put into a shaking 
water bath for 30 min, 1 h, and 2 h at 100 rpm; the tissues are then removed54; and the 
fluorescence of each sample before and after the treatment is analyzed as described above. 
4.2.2.10 Statistical data analysis 
       The study is designed according to the Box–Behnken experimental design method90. 
The polynomial Equations relating the independent variables to dependent variables are 
obtained by Box–Behnken design software (JMP8, SAS Institute), which is used for response 
optimization. 
       The results are expressed as the mean of at least 3 experiments ± the standard error 
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of the mean (SEM). Statistical data analysis is performed using the student t-test; two tails 
with 95% confident interval (p < 0.05) as the minimal level of significance. 
4.3 Results and discussions 
4.3.1 Synthesis and characterization of chitosan-TGA conjugates (TCS) 
       TGA is covalently attached to chitosan by the formation of amide bonds between 
the carboxylic acid groups of the TGA and the primary amino groups of the chitosan. To 
achieve this, the carboxylic acid moieties of the TGA are activated by the EDC. The addition 
of NHS stabilizes the amine-reactive intermediate and increase the efficiency of the 
EDC-mediated coupling reactions. The synthesis is performed at a pH < 5 to avoid the 
formation of the disulfide bonds by air oxidation since, at pH < 5, the formation of disulfide 
bonds can be excluded due to the low concentration of the thiolate anions81. 
4.3.2 Proton nuclear magnetic resonance (1H-NMR) spectroscopy analysis of TCS  
       Based on the results of the NMR spectroscopy (Fig. 4-1), amide bond with chemical 
shift δ = 8.22 is indeed formed and identified in chitosan-TGA conjugate when EDC and 
NHS are used. The control, which is prepared by the same method as of the conjugates but 
omitting EDC and NHS, exhibits no peak of the amide bond (Fig. 4-1). 
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Fig. 4-1. 1H Nuclear Magnetic Resonance (NMR) spectrum of the synthesized TCS 
conjugate and starting materials. 
4.3.3 Formulation and characterization of TCS NPs 
      The Box-Behnken design utilized in this study has several advantages. It requires 
fewer runs in comparison with other experimental designs. Three factors are chosen as 
independent variables: X1= concentration of TCS (w/v %), X2= TPP/TCS weight ratio, X3= 
drug/TCS weight ratio. Each factor is studied at three levels, represent with -1, 0 and 1. Two 
dependent variables: Y1= EE%, Y2= particle mean diameter (nm) are chosen as response. It is 
also able to avoid the extreme conditions as it does not contain combinations where all the 
factors are at their highest or lowest levels91. According to the acceptability criteria for nano 
encapsulation process, a p-value of less than 0.1, and a R2 value of more than 0.9, is required. 
Since the polynomial Equations for Y1 fit well (p = 0.0012, r2=0.98 > 0.90) (Fig. 4-2 A)84, it 
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can be used for Y1 response optimization purposes. The polynomial Equ. 4-10 below 
expresses the influence of the independent variables on Y1 (EE%): 
       Y1 = 5.14 + 2.87X1 + 3.10X2 - 3.40X3 + 2.80X1X2 - 1.97X1X3 - 1.88X2X3 + 3.10X12 - 
1.03X22  -  2.78X32              (4-10) 
 
 
Fig. 4-2 A: Curve fitting of Y1 (EE%), where R2=0.98; B: Standardized Pareto chart showing 
the standardized effect of the formulation variables and their interaction on Y1. X axis 
indicates the t ratio of the variables. Bars extending pass the vertical line indicate values 
reach statistical significance (α=0.05). C: Prediction profiler showing the effect of the 
formulation variables on EE% (Y1). 
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       A Pareto chart is constructed in Fig. 4-2 B to visualize the significance of the 
variables in Equ. 4-10. The values on the X-axis of the Pareto charts represent the 
standardized effects, which are the t values calculated base on the following Equ. 4-11: 
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       Ex is the estimate of factor effect, which is the coefficient in Equ. 4-10, SEe is the 
standard error of the factor effect55. The obtained t, which indicates the main effect of the 
independent variables and interactions on Y1value, compare to a tabulated critical t value 
(tcritical = 2.571at p < 0.05), which is determined at α=0.05 for residual degrees of freedom 
(df), where df = 556; tcritical is shown in the vertical line in the Pareto chart. The factors whose 
length passed the vertical line indicate significance on the response value57. The positive sign 
of the coefficient shows a positive effect on the responses size, while the negative signs 
indicate a negative effect. 
       According to Fig. 4-2 B, X1, X2, X3, X1*X1, X1*X2, X3*X3, X1*X3 and X2*X3 all 
contribute substantially to the EE%. TCS is used in this study as a polymeric matrix; the 
encapsulation of drug is based on the interaction between amino groups of TCS and 
phosphate groups of drug. Higher CS concentration (X1) means more total available amino 
groups in CS molecules, and more drug molecules could interact with TCS through 
electrostatic forces. Thus the EE% increases with the increasing of X1, and X1*X1effectsthe 
EE% positively based on the same reason. From Fig. 4-2 B and C, the concentration of CS 
(X1) has a curvilinear effect on the EE%. Below the coded value of -1, the EE% begins to 
increase. It may be due to the decreased viscosity effect at a lower concentration. It has 
already been reported that low viscosity associated with decreased CS concentration allows 
the drug to move around the polymer chain, and consequently improves entrapment of the 
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drug92.TPP works as the cross linking agent; manymore polymer molecules could be linked 
together and form NPs while increasing the ratio of TPP/CS (X2). The EE% increased with 
the TPP/TCS (w/w) (X2) linearly. Since both CS and TPP strengthen the mass and cross link 
density of the polymeric matrix, the combination of X1*X1 and X1*X2 also show a positive 
effect on EE%. An increase of drug/TCS (w/w) X3 has a decreasing effect on the EE%. The 
higher the relative amount of drug to polymer in the solution (X3), the lower the EE%, 
because fewer polymers would be available for drug encapsulation. Therefore, the 
combination of X1*X3 and X2*X3 show a negative effect on the EE% (Y1). It also appears that 
the EE% (Y1) correlated curvilinearly with X3. The drug/TCS ratio (X3) appears to increase 
the EE%. A possible reason is that the aqueous solution of TFV is weak acid with two pKa 
values at 3.8 and 6.793. At high concentration, TFV possibly affected the pH of the solvent, 
which is conducive to theionization of CS or TCS. The subsequent water solubilization is 
needed for effective cross linking with TPP92. However, this effect is limited by the TFV 
water solubility (1.87 mg/ml in water)61. In Fig. 4-2.C, it is evident that a higher level of X1, 
X2 and a lower level of X3 favored the higher EE% (Y1). Tab. 4-2 shows the results from the 
ANOVA.  
Tab. 4-2. ANOVA for EE% (Y1).  
Response Source DF SS MS F ratio P value 
Y1 Model 9 363.72 40.41 24.88 0.0012 
Error 5 8.12 1.62   
Total 14 371.84    
Note: DF: degree of freedom, SS: sum of square, MS: mean sum of square, F ratio: Model 
MS/error MS 
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       Based on Equ. 4-10 and the interaction plot shown in Fig. 4-2, the optimal 
formulation, which exhibited the highest EE% (25.78%±3.80%) is selected, X1, X2, and X3 
are 1, 0.96, and -1. 
       To confirm the analysis, a check point analysis is performed. Two random points out 
of the 15 runs of the experiment (-0.5, -0.5, -0.5) and (0.5, 0.5, 0.5) and the theoretically 
optimum point resulting from the statistical model (with the three factors set at X1 = 1, X2 = 
0.96 and X3 = -1) is selected. As shown in Tab. 4-3, the EE% of the tested points are close to 
the predicted values.  
Tab. 4-3 Checkpoint Experiments Comparing Measured and Predicted EE% (n=3) 
Run 
no. 
X1 X2 X3 
Measured Y1 
± SEM 
Predicte
d Y1 
Error% 
of Y 1 
p value 
(Y1) 
t value 
(Y1) 
C1 - 0.5 - 0.5 - 0.5 3.90 ±1.01 4.81 -18.09 0.46 0.90 
C2 0.5 0.5 0.5 6.79 ±0.80 7.37 -7.87 0.54 0.72 
C3 1 0.96 - 1 22.60 ±1.06 25.78 -12.34 0.10 3.00 
 
       The differences between the measured and predicted values are not found to be 
statistically significant (p> 0.05). According to Student’s t test, the t value of the optimal 
point (C3) is 3.00 (df = 2, α = 0.05, tcritical = 4.30), which indicates that the optimal EE% 
(22.60%) obtained from the experiment appeared to be close to the prediction (25.78%) 
derived from the model. The other two checkpoints (C1 and C2) led to similar responses (t 
value is 0.90 and 0.72). Thus, it can be reasonably concluded that under these checkpoint 
conditions, the model fits the data satisfactorily and are valid for predicting the EE%. The 
model prediction Equation is an acceptable tool to predict the EE% of NPs in this study. The 
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NP samples used for all the assays below are prepared with the optimal condition. 
       However, the R2 of the polynomial Equation for particle mean diameter Y2 (0.67) is 
below the threshold for acceptability (0.70)84. The possible reason for this is the presence of 
the thiol groups on TCS chains. It is noteworthy that the molecular weight of TCS (10-150 
kDa) is relatively lower than that of CS (50-190 kDa). The size of CS based particles is found 
to be the proportion to the macromolecules’ molecular weight (data not shown). In contrast, 
there is no apparent difference in particle mean diameters of CS NPs (240.1 nm) and TCS 
NPs (252.3 nm) (Tab. 4-4).  
Tab. 4-4. Effect of DL-dithiothreitol (DDT) on Size, Zeta potential and EE% of CS and TCS 
NPs (*: p < 0.05; **:p < 0.01). Data are given as mean ± SEM for n=3. 
NPs Mean 
diameter (nm) 
PDI Zeta 
potential 
(mV) 
EE (%) Drug 
Loading 
(w/w %) 
CS 240.1 ± 3.3 0.298 ± 0.002 43.9 ± 0.6 5.4 ± 1.0 0.51 ± 0.09 
CS+DDT 245.9 ± 28.1 0.212 ± 0.029 44.4 ± 5.4 6.5 ± 0.6 0.61 ± 0.06 
TCS 252.3 ± 16.3 0.317 ± 0.052 21.4 ± 2.4 19.4 ± 1.1 1.62 ± 0.11 
TCS+ DDT 113.0 ± 7.5** 0.305 ± 0.020 20.2 ± 3.2 6.5 ± 
1.4** 
0.61 ± 0.13 
 
       Thus it is reasonable to infer that initially, the TCS tends to form small NPs. 
However, the superfluous thiol groups have strong tendency to form inter- and 
intra-molecular disulfide bonds with each other. These thiol groups provide a cohesive force 
to link the small fragments to form larger particles, and lead to unpredictable particle 
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aggregation following the formation of disulfide bonds as a result. This hypothesis is 
confirmed by the dramatic effect of DDT on the particle mean diameter (Tab. 4-4). DTT is an 
agent thatcan reduce the typical disulfide bond via two sequential thiol-disulfide exchange 
reactions94. After adding DDT, the mean diameter of TCS NPs is significantly reduced from 
252.3 nm to 113.0 nm, while that of the CS NPs remained constant (from 240.1nm to 245.9 
nm). The EE% also decreased with DDT, which indicates that the formation of the disulfide 
bond favored drug entrapment by thiolated NPs. The surface charge of the NPs is (as 
expected) positive under these experimental conditions. The zeta potential of the TCS NPs is 
2-fold lower than that of the CS NPs due to the presence of thiol groups. The positive surface 
charge of the CS based NPs is due to the amino groups95. Since the thiol bearing side chains 
are covalently attached to this primary amino group, it appeared that the existence of bearing 
chains in the TCS reduced the charge density by half. It is unaffected by DTT. 
       SEM and TEM image confirmed the morphology and size data of the CS and TCS 
NPs (Fig. 4-3)34. These NPs exhibit a spherical shape with a diameter ranging from 100 to 
500 nm. 
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Fig. 4-3 Scanning electron microscopy (SEM) of CS NPs (A) and TCS NPs (B), and 
transmission electron microscopy (TEM) of CS NPs (C) and TCS NPs (D). All of the four 
images are obtained with samples prepared with X1 = 1, X2 = 0.96 and X3 = -1, respectively.  
4.3.4 In vitro Release study 
       Recently, TFV containing hydroxyethyl cellulose (HEC) gel is developed as a 
bioadhesive vaginal drug delivery system that appears safe and effective in preventing HIV 
infection21a. In this study, TFV loaded HEC gel is used for comparison with the CS and TCS 
NPs with respect to the drug release profiles. The drug release profiles are shown in Fig. 4-4. 
Approximately, 84% and 95% of cumulative amounts of TFV are released from HEC gel 
within 24 and 48 h respectively. In the case of the CS and TCS NPs, the percent cumulative 
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amount release of TFV is 13% and 31% in 24 h, 19% and 39% within 48 h, respectively, and 
remained constant up to 198 h. These results indicates that the drug release rate is much 
faster from the HEC gel. The controlled release of TFV is clearly observed in the case of both 
the CS and TCS NPs. 
 
Fig. 4-4 In vitro drug release profiles from CS and TCS NPs, in VFS (pH = 4.2), (n = 3). 
Both samples are prepared with X1 = 1, X2 = 0.96 and X3 = -1, data are shown as mean ± 
SEM (n=3). 
       In order to predict and correlate the release behavior of the CS and TCS NPs, it is 
necessary to fit the release data into a suitable mathematical model. The results of curve 
fitting of drug release kinetics into different mathematical models are given in Tab. 4-5.  
Tab. 4-5 Curve Fitting of the Release Kinetics of TFV from CS and TCS NPs 
 CS NPs  TCS NPs  
 k r2  k r2 
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Zero-order model 0.300 0.987  0.312 0.870 
First-order model 0.004 0.990  0.005 0.936 
Higuchi model 4.376 0.973  4.848 0.967 
 
       The zero-order rate describes the systems where the drug release rate is independent 
of its concentration. In the first-order release systems, drug release rate is concentration 
dependent. Higuchi’s model describes the release of drugs from an insoluble matrix as a 
square root of a time-dependent process based on Fickian diffusion67. The release constant is 
calculated from the slope of the appropriate plots, and the regression coefficient (r2) is 
determined. It is found that the in vitro drug release of the CS NPs is best explained by 
first-order model, which is the dominant extended release profile found in hydrophilic matrix 
systems, as the plots shows the highest linearity (r2 = 0.990). The release rate is drug 
concentration gradient driven. This result is consistent with a previous report related to the 
tea catechins release for CS NPs95. The drug release from TCS NPs fit well the Higuchi’s 
Equation, as the plots shows the highest correlation coefficient(r2 = 0.967)96. The insoluble 
matrix is generated by the disulfide bonds that exist only in TCS NPs in this study. The inter 
disulfide matrix could prevent the TFV molecules from escaping out of the particles and 
further decrease the release rate of TFV. 
       The average daily release of TFV is 12% from the CS NPs and 14% from the TCS 
NPs. As the drug loading of the two kinds of particles are 0.51% (w/w) and 1.62% (w/w) 
(Tab. 4-4), about 0.6 × 10-3 mg and 2.6 × 10-3 mg drug could be released from 1 mg of CS 
and TCS NPs every day. Women of reproductive age produce fluid at a rate of approximately 
6 ml/day71;the EC50 value for TFV is about 5 μM97.Therefore, about 14.6 mg of the CS NPs, 
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or 3.9 mg the TCS NPs, would be able to provide the daily requirement of TFV for an adult 
woman patient, which is feasible considering that the average vaginal suppository that could 
be measured as an additional vehicle had a weight of five grams. 
4.3.5 Cell culture 
4.3.5.1 Cytotoxicity studies 
       An ideal vaginal drug delivery system has no impact on the viability, function, and 
structural integrity of the vaginal epithelium. The selected vaginal epithelial cell line 
VK2/E6E7 and human endocervical epithelial cell line End/E6E7 are used to test the effects 
of NPs on cell membrane integrity and cell viability. The LDH membrane integrity assay is a 
fluorometric assay that is used to measure the release of LDH from cells with a disrupted 
membrane98. After 4 h, 24 h, and 48 h, the extent of release of LDH from the cells incubated 
with NPs is no more than 10% higher than that of media (Fig. 4-5). The CS and TCS NPs and 
free TFV caused a non-significant release of LDH. MTS is a tetrazolium compound that is 
bioreduced by viable cells into formazan. The amount of formazan produced is proportional 
with the number of living cells99. The viability test provided the results that are consistent 
with the LDH assay, except the TFV led to 17% reduced cell viability of VK2/E6E7 cell line 
after 48 h incubation. But the reduction didn’t appeared in cells treated by TFV loaded NP, 
which indicates the NPs may even decrease the cytotoxicity induced by drug. 
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Fig. 4-5 Cytotoxicity study of CS and TCS NPs. Top panel: percent LDH release of 
VK2/E6E7 cell line (A) and End/E6E7 cell line (B), percent viability of VK2/E6E7 cell line 
(C) and End/E6E7 cell line (D) and percent viability of L. cripatus (E). Bottom panel: L.
cripatus under microscopy after incubation with blank CS NPs, TFV loaded CS NPs, Blank 
TCS NPs, TFV loaded TCS NPs, free TFV, Media and Triton-X (from left to right) (F). NPs 
are prepared with X1 = 1, X2 = 0.96 and X3 = -1, data are shown as mean ± SEM (n = 3).  *: 
p < 0.05 vs media, **: p < 0.01 vs media.  
       In both assays, no statistical difference is observed by t-test between the media 
control and NPs, which indicates a likely non-cytoxic nature of the CS and TCS NPs. 
Therefore, both the CS and TCS NPs can be regarded as non cytotoxic for vaginal cell lines 
after 48 h. However, these assays are short term studies. The long term effect of the NPs to 
the vaginal cell lines and vaginal tissue remains to be seen in the future work. 
       The vagina has natural flora, the natural flora protects other microorganisms from 
growing in the vagina and cause infections. When the natural flora is disturbed, infection can 
set it and cause an unpleasant odor. The microbicide formulations should not disturb the 
normal vagina flora. L. crispatusis, a predominant normal vaginal floral species10. It is used 
here as model bacteria since it can produce hydrogen peroxide (H2O2) and lactic acid, which 
could maintain the low pH environment and provide a natural barrier for HIV transmission48a. 
No statistical difference is observed between either the media control and the NPs after 
incubation for 4, 24, and 48 h (Fig. 4-5). These results suggest that neither the CS NPs, nor 
the TCS NPs are harmful to the L. crispatus within 48 h. 
       Triton X-100 could dissolve the lipid on the cell membrane and increase the 
membrane permeability leading to cell death. After the treatment for 48 h, the bacteria 
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incubated with the NPs, free TFV and media appeared to be intact and rod-like structures as 
previously reported morphology of L. crispatus100. While the integrity of bacteria incubated 
with Triton X-100 is destroyed, this result indicates that both the CS and the TCS NPs are 
harmless to the L. crispatus within 48 h. 
4.3.5.2 Cellular uptake study 
       Particles labeled with fluorescent dyes are frequently used to study cellular uptake 
quantitatively by a microplate reader and flow cytometry. Based on an earlier study, the 
reaction between the isothiocyanate groups of FITC and the amino groups of CS is a stable 
covalent bond49. Little FITC could leach out from the NPs over 48 h under in vitro conditions. 
Thus, the intracellular fluorescence cannot be due to the uptake of dye released or dissociated 
from the NPs. Fig. 4-6 shows the percentage of the CS and TCS NPs taken by VK2/E6E7 (A) 
and End/E6E7 (B) cell lines. It is evident that more particles are engulfed by cells with longer 
incubation period, due to extended exposure. The CS NPs show similar properties and 
behavior as the TCS NPs in both cell lines. 
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Fig. 4-6 Top panel: the particle uptake efficiency of FITC labeled CS and TCS NPs on 
VK2/E6E7 cell line (A) and End/E6E7 cell line (B). Cells are incubated with NPs for 4, 24 
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and 48 h, data are shown as mean ± SEM (n = 3). Bottom panel: NPs cellular uptake assessed 
by flow cytometry (Count. vs FITC fluorescence intensity); VK/E6E7 cell line treated with 
media (C), FITC labeled CS NPs (D), FITC labeled TCS NPs (E); End/E6E7 cell line treated 
with media (F), FITC labeled CS NPs (G), FITC labeled TCS NPs (H) for 48 h. NPs are 
prepared with X1 = 1, X2 = 0.96 and X3 = -1. 
       The quantification of the percent of cell uptaking FITC-loaded NPs is investigated 
by using flow cytometry. The fluorescence intensity curves of the cells treated by 
FITC-loaded NPs are shown in Fig. 4-6 (Bottom panel). The cell number is on the Y-axis, 
while the X-axis is fluorescence intensity which indicates the number of particles internalized 
by the cells. The shifting of the peak to the right along the X-axis means an intensity increase 
with increasing concentration of FITC labeled NPs. In VK/E6E7 cell line, the percentage 
FITC-positive cellsare90.1% for the CS NPs and 99.3% for the TCS NPs. In End/E6E7 the 
values are 92.6% and 98.6% for the CS and TCS NPs, respectively. A significant uptake of 
NPs is observed in both cell line streated with different NPs compared to the control. The 
results confirmed that these NPs are successfully internalized into the vaginal cells. 
       The uptake is confirmed by fluorescence microscopy. Fig. 4-7 shows the localization 
of NPs in cells. Cell membrane is observed by phase contrast microscopy. A blue 
fluorescence dye, Hoechst 33342, is used to stain the nucleus. It can bind to the minor groove 
of DNA and impart a blue color to identify the nucleus. The fluorescence signal of FITC 
labeled NPs in the cells is detected by the FITC filter. At 48 h after incubation a high level of 
uptake of FITC-labeled NPs by both VK2/E6E7 and End/E6E7 cells is observed by 
fluorescence microscopy. 
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Fig. 4-7 In vitro localization of FITC-labeled CS and TCS NPs in VK2/E6E7 and End/E6E7 
cell lines by fluorescence microscopy. Cells are observed under phase contrast microscopy, 
DAPI and FITC filters are used to observe the nucleus (blue) and the NPs (green), 
respectively. Then the three images are merged. 
Inhibition of cellular uptake study 
       The result of uptake inhibition is shown in Fig. 4-8.  
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Fig. 4-8 Effects of inhibitors on uptake of FITC-labeled NPs on VK2/E6E7 cell line (A) and 
End/E6E7 cell line (B). : CS NPs; : TCS NPs. Cells are incubated with NPs for 24h 
and lysed by 1% Triton X. NPs are prepared with X1 = 1, X2 = 0.96 and X3 = -1, data are 
shown as mean ± SEM (n=3).  
       The cell viability after treated with the inhibitors is shown in Fig. 4-9.  
 
Fig. 4-9 Percent viability of VK2/E6E7 and End/E6E7 cell lines after treated with inhibitors. 
       The inhibitors did not reduce the cell viability. Cytochalasin D is an actin filament 
modifier that can inhibit actin polymerization101. Cytochalasin D led to 15% reduced 
internalization of TCS NPs in End/E6E7 cell line, indicating that cytoskeleton reorganization 
might be a route of the TCS NPs uptake by the End/E6E7 cell line, and actin microfilaments 
contributed significantly in End/E6E7 cell line. Indeed, actin microfilaments are identified in 
epithelial cells of rat uterine102. Actin is the driving force for uptake, which decreased in the 
absence of the actin filaments. Macropinocytosis is dependent on the actin assembly at the 
cell membrane103. During macropinocytosis, the rims of the membrane fold extending from 
 82
the surface and fuse back with the plasma membrane, which is called membrane ruffling104. 
Cytochalasin D induces depolymerization of actin filaments formed and as a result inhibits 
the membrane ruffling. However, this entrance mechanism is excluded in this study 
sincephorbolmyristate acetate (PMA), a macropinocytosis stimulator, did not increase 
particle internalization in any cell line, indicating that the macropinocytosis is not involved in 
NP uptake. An actin assembly dependent entrance mechanism excluding macropinocytosis is 
involved in the uptake of the TCS NPs in the End/E6E7 cell line. Chloropromazine inhibited 
clathrinmediated permeation by disrupting the assembly-disassembly of clathrin105. The 
clathrin pathway is also known as receptor-mediated endocytosis. Particles entering the cell 
via the clathrin pathway are believed to attach to the plasma membrane by specific binding to 
the receptor, then a coated pit which is a specialized region of the membrane that is coated 
with clathrinis formed106. Treatment with chlorpromazine did not reduce the uptake of NPs 
significantly because there is no specific ligand present on the surface of these NPs that can 
interact with the receptors. Under genistein treatment, respectively, 51% and 35% reduction 
of the CS and TCS NPs in the VK2/E6E7 cell line, and 31% and 30% reduction of the CS 
and TCS NPs in the End/E6E7 cell line are observed. These reductions are statistically 
significant compared to the control. Genistein results in the greatest reductions in both cell 
lines. Caveolae is a specialized type of lipid rafts that is a flask-shaped invagination in the 
plasma membrane107.The caveolae associated protein, such as caveolin-1and caveolin-2, are 
expressed in a wide type of human cells, including epithelial cells108. Genistein is an inhibitor 
of caveolin-dependent endocytosis that is used to block lipid raft-mediated endocytosis. In 
caveolae-mediated internalization, NPs interact through non-specific charge interactions with 
the cell. Since both the CS and TCS NPs are positively charged, the cationic charge on the 
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particle surface promotes their electrostatic interaction with the negatively charged cell 
surface, leading to an enhanced cellular uptake viacaveolin pathway that is 
receptor-independent109. It has been previously reported that the particle size also contributes 
to the internalization pathways. Particles with a diameter under 200 nm enter cells 
preferentially via clathrin-mediated endocytosis; particles over 200 nm are more likely to go 
through the caveolin-mediated endocytosis110. The mean diameters of both the CS and TCS 
NPs are above 200 nm. This could be another reason why the caveolae-mediated pathway 
favored these NPs. It is also consistent with a previous report that PLGA NPs with a mean 
diameter over 200 nm are primarily internalized via the same pathway[9]. Indeed, the 
internalized caveolae fuse with caveosomes, which could deliver their contents into other 
subcellular compartments. In comparison with the clathrin-dependent endocytosis, the 
caveolae internalization pathway could avoid the acidic and harmful milieu111. In summary, 
caveolin-dependent endocytosis is the most productive route for uptake of these NPs on both 
cell lines, while cytoskeleton reorganization also contributes as a minor fraction, though the 
mechanism to which it occurs only on the End/E6E7 cell line is still not clear. A similar result 
has been reported using the CS-DNA complex on the HT1080 cells112. However, since none 
of these inhibitors completely eliminate the particle uptake, it is evident that other 
internalization pathways are involved. The same NPs could be internalized via different 
pathways. For example, it remains to be known if megalin (an endocytic receptor in 
reproductive tissue for sex hormone binding globulin) also act as a pathway for these NPs’ 
uptake113. 
4.3.6 Bioadhesive studies 
       The mucus layer covering the epithelia could protect the epithelia against 
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mechanical and chemical damage. It consists mainly of glycoprotein chains with 
cysteine-rich subdomains114. The enhanced mucoadhesive properties of thiomers, such as 
TCS, are believed to be based on an interaction of thiolated groups of polymers with the 
cysteine-rich subdomains of mucus glycoprotein. The evidence of these disulphide bridges 
formations has been provided in previous literatures30, 115. 
       Porcine vaginal tissue shows a high level of similarity to human vaginal tissue in not 
only ultrastructural organization and lipid composition, but also the secretions, in terms of pH 
and inflammatory responses73. These similarities in structure and function have led to the use 
of porcine tissue as a promising experimental tissue model in studies of the vaginal drug 
delivery system. Preliminary study shows that the mucosal tissue remains vital after3 h of 
death116; no significant difference has been shown in the histological structure or water 
permeability of the mucosal tissue snap frozen in liquid nitrogen as comparison with fresh 
tissue117. 
       Fig. 4-10 shows the mucoadhesion of the CS and TCS NPs.  
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Fig. 4-10 Top panel: concentration dependent percent mucoadhesion by infusion method (A); 
and time dependent percent mucoadhesion by immersion method (B). : CS NPs; : 
CS-THA NPs. Bottom panel: fluorescence microcopy of FITC-CS NPs suspension (3 mg/ml) 
(C), FITC-TCS NPs suspension (3 mg/ml) (D), thin sections of porcine vaginal tissue treated 
with suspension A (E), suspension B (F) and media (G). H: H&E staining of porcine vaginal 
tissue. NPs are prepared with X1 = 1, X2 = 0.96 and X3 = -1, respectively. Data are shown as 
mean ± SEM (n=3). 
       According to Fig. 4-10 A, the mucoadhesive property of the TCS NPs is 4-5 fold 
higher in comparison with that of the unmodified CS NPs, which is consistent with the 
previous report118. The percent mucoadhesion of lower concentration TCS NPs increased 
considerably when the incubation time is prolonged as shown in Fig. 4-10 B. The formation 
of disulfide bonds between the TCS NPs and the mucus gel layer is based on a cross-linking 
process via the thiol/disulfide exchange reactions or a simple oxidation process of free thiol 
groups29. By delaying the reaction time, more disulfide bonds can be formed from oxidation 
of the thiol groups. Hence, the mucoadhesion adhered covalently on the surface of the mucus 
layer. However, the increase of the percent mucoadhesion of higher concentration NPs (3 
mg/ml) is not statistically significant compared to that of the lower concentration NPs (1 
mg/ml); perhaps because of the limited number of reactive groups on the tissue surface. The 
maximum percent of bioadhesion is 65% (± 3%) with the 200 nm sized NP for a 2 h duration. 
The data indicates that mucoadhesion is a time and size dependent process. 
       The bottom panel of Fig. 4-10 shows the tissue sections visualized using a 
fluorescence microscopy. The tissue treated with the CS NPs shows a very weak fluorescence, 
while a strong intensity is observed from the tissue treated with fluorescently labeled TCS 
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NPs. The FITC label efficiency of the TCS is 1.5 times that of CS (data not shown). However, 
it is obvious that the amount of the TCS NPs adhered on the surface of the vaginal tissue is 
much larger than that of the CS NPs on the tissue. 
4.4 Conclusion 
       In this work, it is reported for the first time that an anti-HIV microbicide (TFV) 
loaded thiolated CS can be a highly mucoadhesive (65%) and non-cytotoxic vaginal drug 
delivery system. The in vitro drug release, cytotoxicity assays, and mucoadhesion studies 
suggest that TCS NPs have the potential to be a controlled release, safe, and bioadhesive 
microbicide delivery system. These properties make thiolated CS NPs a good candidate for a 
topical vaginal microbicide delivery system for further study related to the quest of the 
prevention of HIV transmission. 
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CHAPTER 5 
THIOLATED CHITOSAN COATED SODIUM ALGINATE MULTILAYER 
MICROPARTICLES FOR ENHANCED DRUG LOADING AND MUCOADHESION 
5.1 Rationale 
       An ideal vaginal drug delivery system should be easy to administer, not cause 
discomfort to improve patient compliance and have a reduced number of doses required to 
the treatment119. To meet these requirements, various vaginal drug carriers have been 
developed79, 120. However, in most of these formulations, the encapsulation of a water soluble 
small molecular drug is a serious problem associated with low drug %EE payload. Recently, 
a special attention has been focused on the development of spray dried microparticles 
(MPs)18a. 
       Spray drying is a rapid and simple process base on the evaporation of the solvent. 
The atomized polymeric droplets containing the drug are transformed in solid particles by a 
stream of heated air121. The spray drying method not only typically produces spherical MPs 
with a narrow size distribution, but also enables the encapsulation of both hydrophilic and 
hydrophobic drugs with relatively high efficiency and yield122. 
       The main advantages of MPs over traditional vaginal dosage forms such as gels, 
creams, rings, and films are: the generation of a sustained long term drug release following 
the application of a single dose, a proper spreading over the vaginal epithelium, the 
protection of the drugs and capacity to reduce drug toxicity. To further prolong the residence 
time onsite of the treatment, a thiolated chitosan (TCS) is used to coat the MPs. TCS is 
chitosan (CS) with thiol groups immobilized on the polymer backbone. They have been 
shown to possess high mucoadhesive properties due to the thiol groups present on the CS 
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backbone can form disulfide bonds with the thiol groups present on the mucus 
substructures30. 
       In this study, a hydrophilic anti-HIV microbicide, TFV (water solubility 1.87 mg.ml, 
logP -1.5), is encapsulated within the spray dried alginate MPs. The MPs are coated with 
TCS base on the charge-charge interaction between alginate and TCS. It is postulated that 
these MPs may provide prolonged retention time as well as controlled release, and could be a 
potential vaginal drug delivery system with increased encapsulation of water soluble small 
molecule drugs.  
5.2 Materials and methods 
5.2.1 Materials 
       Sodium alginate, CS with the weight molecular weight of 50-190 KDa, mucin, 
periodic acid, Schiff reagent kit and benzalkonium chloride (BZK, 2 %w/v) are purchased 
from Sigma Aldrich (St. Louis, MO, USA). TFV is purchased from Zhongshuo 
Pharmaceutical Co. Ltd. (Beijing, China). Sodium triphosphate pentabasic (TPP) is supplied 
by Fisher Scientific (Pittsburgh, PA, USA). The CytoTox-ONE™ and CellTiter 96™ 
Aqueous kits are purchased from Promega (Madison, WI, USA). 
5.2.2 Methods 
5.2.2.1 Formulation of spray dried MPs 
       To prepare TFV loaded alginate MPs, different amount of sodium alginate and TFV 
(Tab.1) is dissolved in 40 ml of deionized water, the ratio of sodium alginate to TFV is 5:1 
(w/w). The solution is then spray dried using a Buchi Mini Spray Dryer, Model 290 (Buchi 
Laboratoriums - Technik AG, Flawil, Switzerland). Then, the formulated MPs are stored at 
4 °C for further analysis. 
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       In order to optimize the preparation conditions, a custom design with 3 factors and 
16 run is used to study the effect of the formulation parameters on the yield. The independent 
variables, namely, molecular weight of sodium alginate, concentration of the sodium alginate 
solution, and inlet temperature, are represented by X1, X2 and X3, respectively. The percent 
(%) yield, which is the dependent variable is represented by Y. These variables and their 
coded factors are listed in Tab. 5-1. All independent variables in this work are selected based 
on preliminary experiments performed (data not shown). 
Tab. 5-1: Independent and dependent variables and their levels in custom design 
   
5.2.2.2 Percent yield  
       The yield is calculated by the ratio of total amont of the resulting sodium alginate 
MP powder to the total mass of amount of sodium alginate originally contained in the 
atomized liquid feed volume (Equ. 5-1). 
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5.2.2.3 Preparation of the multilayered MPs 
       For the preparation of MPs, a layer-by-layer method described by Li, et al. is 
employed123. Briefly, 40 mg of CaCl2 and 2 mg of TCS are dissolved in 1 ml of acidic acid 
Variables Value 
Independent Molecular weight of sodium alginate (X1) Low High 
Concentration of sodium alginate (X2) 5 mg/ml 15 mg/ml 
Inlet temperature (X3) 100 °C 150 °C 
Depentent  Yield (Y)   
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solution (pH 5). A total of 1 mg of spray dried alginate MPs are subsequently suspended into 
the above solution. After the resulting suspension is stirred for 2 h. The product is collected 
by centrifugation (Beckman Coulter Inc., Pasadena, CA, USA) at 10,000 rpm for 15 min and 
washed thoroughly with water once. This product is TCS coated single layer MP (SLMP). 
The multilayer MPs are obtained by alternately coating alginate and TCS on the surface of 
the particles. Firstly, alginate and TCS is dissolved in acetic acid solution (pH 5) at a 
concentration of 2 mg/ml, respectively. At this pH, both TCS (pKa 6.5) and alginate (pKa 4.2) 
mainly exist in ionized form124. The SLMPs are suspended in 1 ml of alginate solution and 
stirred at room temperature for 10 min. The particles are centrifuged at 10,000 rpm for 10 
min, washed, and suspended in 1 ml of TCS solution for 10 min. The resulting MPs are 
collected by centrifugation at 10,000 rpm for 10 min and washed with water once. These 
MPs are double layer MPs (DLMPs). The triple layer MPs (TLMPs) could thus be obtained 
by repeating the above operations and so on (Fig. 5-1). 
 
Fig. 5-1 Schematic preparation scheme of the TCS coated multilayer MPs.  
5.2.2.4 Percent drug loading determination using 31P SS NMR 
         31P-P90 MAS SS NMR spectra are acquired on a Tecmag Apollo console 
(Houston, TX) with 8.45 T magnet and homebuilt, 2-channel, wide-bore NMR probes. The 
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1H and 31P Larmor frequenciesare357.2 MHz and 144.596 MHz respectively. 31P spectra are 
acquired on 3 mm probe with MAS spinning frequency and 45º pulse length is 8 KHz and 2 
μs, respectively and signals are represented as chemical shift value; δ: ppm. About 40 mg of 
the MPs sample is taken for each analysis. All experiments are performed at ambient 
temperature without any corrections for sample heating.  
5.2.2.5 Zeta sizer, FT-IR, and SEM is used to proof the formation of multilayers. 
       The zeta potential of the MPs is determined using Zeta sizer (Zetasizer Nano ZS, 
Malvern Instruments Ltd, Worcestershire, UK). Measurements are made in triplicate (n = 3) 
at 25 ºC.  
The surface chemistry is determined by FT-IR. Before analyzing each sample, the 
background is collected at ambient conditions, then the MPs are scanned over the range of 
650 and 4000 cm−1. The FT-IR spectra are recorded by OMNIC V 7.0 spectra software. 
The morphology of the MPs is analyzed by scanning electron microscopy (SEM). A 
small amount of the MP powder is mounted on a 1/2″ aluminum stubs with double-sticky 
carbon tape, and sputter coated (Emitech EMS575SX) with approximately 20 nm thickness 
of gold–palladium alloy. The sample is then visualized under a FEI/Philips XL30 Field- 
Emission Environmental SEM (Philips/FEI, Eindhoven, Netherlands) at 5 kV. Digital images 
are acquired with ORIUSTM SC 1000 11 Megapixel CCD camera (Gatan, Pleasanton, CA, 
USA).The diameter of the MPs in the SEM images are estimated using Image Pro Plus 
software (Image Pro Plus 6.0, Media Cybernetics, Silver Spring, MD, USA). At least 100 
particles counted to generate graph.  
5.2.2.6 In vitro TFV release profile 
       The in vitro release of TFV from different MPs is evaluated using dialysis method125. 
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One milligram/ml of MPs suspension is prepared inVFS or SFS media, prepared according to 
previous reports45-46. This suspension is then placed in Spectra/Por cellulose ester membrane 
dialysis bag (Spectrum Laboratories Inc. Rancho Dominguze, CA, USA) with 10-12 kDa 
molecular weight cutoff and is immersed into 20 mL of the same media at 37 °C in a 
thermostatically controlled shaking water bath (BS-06, Lab Companion, Seoul, Korea). At 
predetermined time intervals, the whole media is removed and replaced by fresh media. The 
concentration of the drug in the media is determined by a GENESYS 10 Bio UV-Visible 
Spectrophotometer (Thermo Scientific, Waltham, MA, USA ) at 259 nm. Each experiment is 
run in triplicate together with a blank. In order to find out the mechanism of drug release from 
the formulations, the data distributions are fitted to various kinetics models (Tab. 5-2), using 
Microsoft Excel add-in DDSolver software126.  
Tab. 5-2 Different release models for model fit analysis of the in vitro data 
Model Equation Parameter(s) 
First-order F=100 · (1-e-k1 · t) k1 
Higuchi F=kH · t0.5 kH 
Baker-Lonsdale ͵
ʹ ሾͳ െ ሺͳ െ
ܨ
ͳͲͲሻ
ଶ
ଷሿ െ ܨͳͲͲ ൌ ݇஻௅ ൉  
kBL 
Korsmeyer–Peppas F=kKP · tn kKP, n 
F represents the fraction of the drug released in time t, k1, kH, kBL, kKP represent the release 
rate constant of different model, n is the release exponent. 
5.2.2.7 Cytotoxicity studies 
       To perform the cytotoxicity studies, VK2/E6E7 (human vaginal keratinocyte) and 
End1/E6E7 (human endocervical epithelial) cell lines are grown in Keratinocytes-SFM 
medium Suped with 1% penicillin/streptomycin and 10% (v/v) fetal bovine serum (FBS). 
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Cells are seeded in 96 well plates at 37°C and humidified 5% CO2 atmosphere till 80% 
confluence is achieved. Then the original cell culture media is removed and substituted with 
media containing alginate MPs, SLMPs, DLMPs and TLMPs with different concentration. 
Media with no MPs and 1% Triton-X 100 is used as negative and positive control samples, 
respectively. The well plates are then incubated at 37°C for 24 h and 48 h. 
       In order to determine the lactate dehydrogenase (LDH) assay, the plates are 
equilibrated at room temperature for 10 min. One hundred microliter of CytoTox-ONE™ 
Reagentis added in each well, followed by 30 s shaking and 10 min incubation at 37°C, 
Finally, 50 μl of stop solution is added. The fluorescence intensity is determined by a 
microplate reader at λex560 nm and λem590.  
       For cell viability determination, after the incubation time, the media in the wells is 
removed and substituted with fresh media. Twenty microliters of CellTiter 96®Aqueous One 
Solution Reagent (Promega, Madison, WI, USA) is added to each well and incubated at 37°C 
for 4h. The absorbance is recorded at a wavelength of 490 nm.  
5.2.2.8 Mucoadhesion study 
       To assess the amount of mucin adsorbed by the MPs, a periodic acid/Schiff (PAS) 
colorimetric method is used127. Briefly, mucin is dissolved in VFS and SFS and the MP 
powder is suspended in the same solution at the ratio of 0.1, 1, and 2 of mucin:MPs. The 
suspension is maintained in the above shaking water bath at 37 °C for 30 min with an 
agitation speed of 100 rpm and then centrifuged at 4000 rpm for 2 min. The supernatant is 
removed, 0.2 ml of periodic acid reagent is added and incubated at 37°C for 2 h, followed by 
addition of 0.2 ml Schiff reagent and incubation at room temperature for 30 min. The 
absorbance of the solution is recorded at 555 nm by UV spectrophotometer. The mucin 
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content is calculated from the standard calibration curve. The sprayed alginate MPs and 
mucin solution without MPs is used as controls. Each experiment is performed in triplicate. 
The mucin adsorption is estimated using the Equ. 5-2: 
ሺΨሻ ൌ  െ  ൈ ͳͲͲΨ˄ͷ െ ʹ˅ 
5.2.2.9 In vivo safety studies 
       Female C57/BL6 mice (8-12 weeks old) with an average body weight of 20 g are 
ordered from Jackson Laboratories (Harbor, ME). All mice are housed (maximum 5 per cage) 
under a 12 h light: dark regime in the University of Missouri-Kansas city (UMKC) 
Laboratory Animal Resource Center (LARC) facility with temperature, humidity, and 
lighting controlled systems and allowed to acclimate for 7 days. Mice are treated with 2 mg 
of subcutaneous medroxyprogesterone acetate  (Greenstone, Peapack, NJ, USA) diluted in 
Lactated Ringer’s saline solution 4-5 days before the treatment to induces and maintain a 
diestrus-like state.  
       The DLMP is suspended in PBS at a concentration of 475 mg/kg. Benzalkonium 
chloride (BZK, 2 %w/v) is used as positive control due to its well-known toxic effects on 
genital tracts, PBS is used as negative control. Once-daily administration is carried out using 
a flexible feeding needle (Cadence, Inc. Staunton, VA, USA). After completion of the 1-day 
and 7-day intravaginal application, mice are euthanized by carbon dioxide (CO2) 
asphyxiation. Their cervico-vaginal tissues are harvested. The collected tissues are formalin 
fixed and embedded in paraffin, and cut into 5-mm sections.  
5.2.2.9.1 H&E staining 
       Serial sections are used for staining with hemotoxylin and eosin (H&E). Images are 
captured using a Nikon Labophot-2 microscope (Nikon Instruments, Inc., Melville, NY) 
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equipped with a PAXCam digital microscope camera and analyzed using PAX-it image 
management and analysis software (Midwest Information Systems, Inc., Villa Park, Illinois). 
5.2.2.9.2 Immunohistochemical (IHC) staining 
        In order to identify the inflammatory cell (CD45) infiltrate, immunohistochemical 
staining is performed in genital tissue sections. Briefly, the sections are de-paraffinized and 
rehydrated using the standard protocol. Antigen retrieval is performed using steam heat 
method in citrate buffer/0.05%Tween-20 for 20 min. The tissue sections are then rinsed with 
Tris buffered saline/0.05%Tween-20 three times, followed by treating with 3% v/v hydrogen 
peroxide in PBS for 10 min and blocked with 10% normal goat serum for 2 h (Vector 
Laboratories, Burlingame, CA).  Anti-CD45 from Santa Cruz Biotechnology, Inc. (Dallas, 
Texas) are diluted in 1.5% normal goat serum to 5 μg/mL (1:50) and applied to the tissue 
sections overnight at 4°C in a humidified chamber. Following the incubation with primary 
antibody, tissue sections are rinsed three times. The appropriate biotinylated secondary 
antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) is then diluted to 5 μg/mL (1:50) 
and applied to tissue sections at room temperature for 1 h. After the incubation with the 
secondary antibody, visualization of the cells is performed using the DAB: Peroxidase 
Substrate Kit (Sigma, Saint Louis, MO) under a Nikon Labophot-2 microscope. The tissue is 
then counter-stained using hematoxylin (Sigma, Saint Louis, MO) and processed through an 
alcohol gradient and xylene before application of a coverslip mounted using cytoseal 60 
mounting media (Richard Allan Scientific, Kalamazoo, MI). Images are viewed and captured 
as described above.
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5.2.2.10 Statistical analysis 
        The result of the custom experimental design is performed and analyzed using JMP 
software (version 8.0, SAS Institute Inc., Cary, NC, USA). Unless otherwise stated, data are 
expressed as mean ± standard deviations (n = 3). Compared to controls, the statistical 
significant difference of a given mean is determined using a student’s t-test. A P value < 0.05 
is considered statistically significant. 
5.3 Results and discussion 
5.3.1 Experimental design and optimization of spray dried MPs 
       The responses obtained by the custom design are described in Tab. 5-3.  
Tab. 5-3 responses obtained by the custom design. 
No. Mw Concentration (mg/ml) Inlet T (°C) Yield (%) 
1 Low 15 150 48.3 
2 Low 10 100 43.9 
3 High 5 150 56.1 
4 High 5 100 44.9 
5 High 15 150 17.4 
6 High 5 150 54.9 
7 Low 5 125 52.5 
8 High 15 100 5.37 
9 Low 5 150 61.2 
10 High 5 100 50.5 
11 Low 5 100 48.6 
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12 High 15 150 20.2 
13 High 10 125 43.2 
14 Low 15 125 40 
15 Low 15 100 14.6 
16 Low 10 150 49.5 
       The overall yield varies from 15% to 60%. The R2 value of the dependent variable is 
0.95, greater than 0.9. From the results of the ANOVA study (Tab. 5-4), the P value is 0.0007, 
less than 0.05. These results indicating a statistically significant model fit at 95% confidence. 
Tab. 5-4 ANOVA analysis of the spray dried MPs  
Response Source DF Sum of squares Mean square F ratio P value 
C1 Model 8 4004.39 500.55 16.57 0.0007* 
C2 Error 7 211.52 30.22   
C3 Total error 15 4215.91    
       The polynomial Equations for the response value is: 
       Y=46.89-5.31X1-14.93X2+7.14X3-5.04X1X2-1.51X1X3+2.83X2X3-5.14X22-4.70X32 
(5-3) 
       In Equ. 5-3, the coefficients of the independent variables show their effects on the 
yield. The coefficients of interaction terms show how the yield changes when the two 
independent variables changed simultaneously. The main effect of all independent variables 
and their interactions on the dependent variable (yield) is shown in Fig. 5-2. The values on 
the x-axis of the Pareto charts represent the standardized effects. The factors whose length 
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passed the blue vertical line (tcritical= 2.36 at P < 0.05) are identified as statistically 
significant42.  
 
Fig. 5-2 Standardized effect of variables and their interaction on yield. The x-axis shows the t 
ratio of the variables, bars extending pass the vertical line indicate values reaching statistical 
significant (P < 0.05). 
       Fig. 5-3 is a desirability and prediction plot showing the effect of the independent 
variables on the yield. The solid black line and the dashed boundary lines represent the 
predicted values of the yield with their 95% confidence data distribution limit, respectively. 
In order to maximize the yield, the optimum condition is selected through the mathematical 
optimization process: low molecular weight, alginate concentration 6.13 mg/ml, inlet 
temperature 142 °C. 
       It is found that decreasing the alginate concentration can significantly improve the 
yield. High inlet temperature and low molecular weight are also capable of improving the 
yield. 
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Fig. 5-3 prediction profiler and desirability plot showing the effect of independent variables on 
yield.  
       To obtain well-dispersed MPs, the concentration of the initial solution has to respect 
some conditions: (1) to generate particles with a relatively high density and good mechanical 
characteristics, the concentration of the polymer should be sufficiently high. (2) to allow its 
homogenous atomization, the viscosity of the solution should be relatively low121. 
       Alginate solution at concentration lower than 5% (w/v) results in the formation of 
droplets but dried powders based on past experience. With low concentration, low content of 
solid and high proportion of water, more water need to be removed at constant temperature 
and flow rate, which leads to incomplete evaporation. To run the spray-drying process 
efficiently and smoothly, 5% (w/v) is selected as the lowest limit of the polymer 
concentration. On the other hand, with increasing concentration resulting in increased 
viscosity. The viscosity is directly proportional to the degree of atomization, which largely 
determines the efficiency of spray drying. 
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       The mechanism of the atomization in spray drying can be summarized as the immediate 
disintegration of liquid. At the nozzle orifice, the contact of the liquid with the high velocity 
gaseous medium creates high frictional force over liquid surface, the liquid is broken up by the 
kinetic energy, forms into smaller droplets. The entire process is the result of turbulence in the 
issuing liquid and the action of air force, however, it is opposed by viscosity. As the feed 
solution’s viscosity increases, more kinetic energy is used to overcome larger viscous force. 
This can be explained using the Reynolds number shown in Equ. 5-4: 
ܴ݁ ൌ ߩݓ݀ߟ ሺͷ െ Ͷሻ 
       Where Re denotes the Reynolds number, ρ is the density of the liquid, w is the fluid 
velocity of the liquid, d is the inner nozzle diameter, η is the viscosity128. 
       An increase in viscosity lowers the Reynolds number and makes turbulence 
generation more difficult. Therefore, less energy of atomization is available for breaking up 
the droplets. The insufficient turbulence and energy transfer causing a wide droplet-size 
distribution throughout the resulting spray, and even a high percentage of liquid remains in 
the center of the spray as a solid jet. These large particles or jet cannot been completely dried 
before they deposit on the drying chamber wall129. Therefore, when viscosity is high, these 
semi-wet particles build up form a wet deposit, or even break off as wet lumps and stream 
down the wall. This is a well-known phenomenon that results in a reduced powder yield130. 
       The effect of molecular weight to the viscosity is shown in the Mark-Houwink 
Equation as follow131: 
        [η] = KMa                                        (5 - 5) 
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       Where K and a are constant (MH constant). Lower molecular weight lead to lower 
viscosity, hence results in higher yield. By increasing inlet temperature, the overall thermal 
efficiency is increased, leading to better drying and higher yield. With lager molecular weight 
resulting in higher viscosities and hence lower yields. 
       Moreover, by increasing inlet temperature, the overall thermal efficiency is 
increased, leading to better drying and higher yield. The effect of inlet temperature on spray 
drying is shown as follow132: 
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       Where ηoverall denotes the overall thermal efficiency, T1 is inlet temperature, T2 is 
outlet temperature, and T0 is the atmospheric temperature.  
The relationship between the actual values and the theoretical values of the yield is 
investigated by a check point analysis. The measured and predicted values of the yield at 
three selected point (two random points and the optimal point) are shown in Tab. 5-5. The 
differences of all the points appear to be statistically insignificant, indicating that this model 
is valid for predicting the yield. 
Tab. 5-5 Checkpoint experiments comparing measured and predicted responses (n = 3) 
Run 
NO. 
X1 X2 
(mg/ml) 
X3  
(°C) 
Measured Y 
(%) 
Predicted 
Y (%) 
Error
% 
t 
valu
e 
P 
value 
C1 Low 7.5 113 53.23 ± 4.75 51.26 4.23 0.41 0.72 
C2 High 12.5 138 37.67 ± 7.54 32.68 15.41 0.66 0.58 
C3 Low 6.13 142 62.62 ± 6.67 58.97 6.19 0.55 0.64 
 103
 
5.3.2 Chatacterization of the MPs 
       Tab. 5-6 describes about the amount of TFV encapsulated in MPs with different 
layers. The amount is presented as a percentage, in comparison with pure TFV (considered as 
100 %). Three trials for each type of NPs are carried out in order to be able to calculate the 
standard deviation by utilizing 31P solid state NMR spectroscopic technique. The drug 
loading slightly decreases when a new layer, which increases the total mass of polymer, is 
coated. The MPs are washed after each coating step, this may also lead to the loss of drug 
dye to the high water solubility of TFV. 
 
Fig. 5-4 31P solid state NMR spectroscopy of the MPs 
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Tab. 5-6 Drug loading in the multilayer MPs, pure TFV is considered as 100 %. 
Formulation Drug loading (%) 
SLMP 17.80±0.30 
DLMP 12.27±0.23 
TLMP 7.17±0.21 
 
       The dominated component on the MPs surface during the coating process can be 
estimated from the zeta potential measurement. A reversal in the surface charge of the MPs is 
expected as oppositely charged polymers are adsorbed onto the surface of the MPs133. As 
shown in Fig. 5-5 A, the zeta potential of alginate and TCS are found to be -42 ± 1.5 mV and 
+35.5 ± 1.5 mV (n = 3). The zeta potential of the spray dried alginate MPs is -41.1 mV . 
After the first coating, the cationic TCS is deposited on the negative charged surface to form 
TCS coated single layer MPs with zeta potential of +25 mV. To generate the double layer 
MPs, the anionic alginate is assembled on the surface, followed by coating of the second 
layer of TCS, for which the zeta potential reversed from −40 mV to +33.0 mV. Finally, the 
last layer of alginate and TCS is conjugated respectively to obtain the trip layer MPs. And the 
final zeta potential changed from −42 mV to +35 mV, suggesting TCS is exposed on the 
surface.  
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Fig. 5-5 Change in zeta potential values (A) and FTIR (B) after coating with oppositely 
charged TCS and sodium alginate (n=3). 
       The coating of different layers is further confirmed by FT-IR (Fig. 5-5 B). Both 
native alginate and native TCS exhibit a broad absorption peak at around 3100 to 3650cm–1 
and weak absorption peaks at 2890 cm–1, attributed to the hydrogen bond stretching vibration 
and the CH stretch, respectively. TCS shows two peaks at 1520 and 1650 cm–1 are due to the 
amide (CO-NH-) and the amine (-NH2) absorption band, respectively. The native alginate 
reveals two sharp peaks at 1610 and 1415 cm–1 assigned to the carboxylic acids (COO–). 
After coating by TCS or alginate, the dominated component on the MPs surface is the same 
polymer. 
       Layer by layer deposition results in a slight increase in the particle size. The average 
diameter of spray dried alginate MPs, SLMPs, DLMPs and TLMPs is found to be 2.01μm, 
2.06 μm, 2.66 μm and 2.83 μm , respectively, As the SEM images and size distribution 
shown in Fig. 5-6. A minimum of 100 PMs for each sample are analyzed. The MPs appear to 
be well dispersed, the increasing in mean diameter with each coating step indicating the layer 
growth. 
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Fig. 5-6 SEM image (left) and size distribution (right) of A: alginate MPs, B: TCS coated 
single layer MPs, C: TCS coated double layer MPs, D: TCS coated triple layer MPs. 
5.3.3 In vitro release profile of the MPs 
       The in vitro release of TFV form the MPs is analyzed up to 5 days. From the release 
profile of the MPs in both VFS and SFS media shown in Fig. 5-7, the release pattern is 
characterized by a short-lasting burst release followed by a longer-lasting sustained release. 
The release rate of TFV is decreased as the number of layers is increased. The spray dried 
alginate MPs are used as control, in which, a burst release is observed. Almost 100% of its 
pay load is released within the first 24 h, as alginate is entirely solubilized without calcium 
chloride and TCS. Calcium chloride is added as a cross-linking reagent. The calcium ions 
and the glucuronic sequences of alginate can interact via charge-charge interaction, each 
calcium ion can attach to two of the alginate strands to form a matrix texture (Fig. 5-1)134. 
Then TCS is deposited on to the surface of the MPs to generate a core-shell structure. After 
TCS coating, the cumulative drug release reduces to 65% and 78% in VFS and SFS, 
respectively. However, TFV can easily diffuse out of the MPs across the single layer of TCS 
shell. In order to further reduce the release rate, the second and third layer of TCS is coated 
as previously described. As a result, the percentage release rate of drug from DLMPs and 
TLMPs decreased to 49% and 41% in VFS, 58% and 43% in SFS media, respectively, as 
analyzed after 24 h. 
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Fig. 5-7 In vitro release profile of drug from alginate MPs, SLMPs, DLMPs and TLMPs in 
VFS (A) and SFS (B) (n=3). 
       To elucidate the release mechanism of the core-shell MPs, their drug release profiles 
are fitted to a series of known release kinetic models in Tab. 5-2. The first-order release 
model represents the system where the drug release rate is concentration dependent. Higuchi 
model is developed to describe the release of water soluble (or low soluble) drugs 
incorporated in solid (or semi-solid) matrixes. Baker-Lonsdale model is developed by Baker 
and Lonsdale from the Higuchi model to characterize the controlled drug release from a 
spherical matrix. This model is generally applied to analyze the release of nano and 
micro-particles. Korsmeyer–Peppas model is a semi-empirical model the n value is used to 
study different mechanisms of the pay load release, of n≤0.5 for diffusion and 0.5 < n≤ 1 for 
mass transfer following a non-Fickian model67. 
       The results of the release data modeling are summarized in Tab. 5-7, In VFS, the 
drug release from SLMPs follow mostly the first-order kinetic, since the value of correlation 
coefficient (r2) is the highest when the data is fit to first-order model, while The drug release 
from DLMPs and TLMPs is governed by the Baker-Lonsdale model. In SFS, the release of 
TLMPs fit the same model as it in VFS, while the release profile of SL and DLMPs can be 
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better described by Korsmeyer–Peppas model, the Korsmeyer–Peppas release exponent (n) is 
less than 0.5, indicating that diffusion is the controlling factor for drug release. 
Tab. 5-7 Mathematical modeling for drug release from different MPs in VFS and SFS. 
Media MP
s 
First-order Higuchi Baker-Lonsdal
e 
Korsmeyer–Peppas 
k 1 r2 k H r2 k 0 r2 k 0 n r2 
VFS 
(pH 
4.2) 
SL 0.04 0.9848 10.04 0.9257 0.003 0.9702 14.895 0.408 0.9471
DL 0.022 0.8462 8.43 0.9344 0.002 0.9909 14.844 0.367 0.9890
TL 0.014 0.8587 7.13 0.9654 0.001 0.9898 10.182 0.417 0.9824
SFS 
(pH7.
2) 
SL 0.106 0.8465 10.58 0.4389 0.004 0.8189 32.331 0.237 0.9074
DL 0.032 0.7557 9.063 0.8209 0.003 0.9554 20.424 0.309 0.9776
TL 0.017 0.8796 7.603 0.9681 0.001 0.9932 11.011 0.413 0.9866
5.3.4 Cytotoxicity study  
       As shown in Fig. 5-8, no significant increasing of LDH release is observed in the 
TFV loaded MPs treated cells compare to that of the negative control (media) .  
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Fig. 5-8 LDH release of cells treated by alginate MPs, SLMPs, DLMPs and TLMPs for 24 and 
48 h. A: VK2/E6E7 cell line 24h; B: VK2/E6E7 cell line 48 h; C: End1/E6E7 cell line 24 h; 
D: End1/E6E7 cell line 48 h, (n=3). 
       3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H- 
tetrazolium (MTS) is a tetrazolium compound. MTS can be converted to a brown formazan 
compound by active mitochondrial reductase enzymes, which exist in living cells only. 
Therefore, this reduction can be directly related to the number of living cells, the formazan 
product is used as an indicator of the cell viability. No significant difference is found between 
the cells incubated with drug loaded MPs and media (Fig. 5-9). These results suggest that the 
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TFV loaded MPs are not toxic to both vaginal (VK2/E6E7) and endocervical (End1/E6E7) 
epithelial cell lines. 
 
Fig. 5-9 Viability of cells treated by alginate MPs, SLMPs, DLMPs and TLMPs for 24 and 48 
h. A: VK2/E6E7 cell line 24h; B: VK2/E6E7 cell line 48 h; C: End1/E6E7 cell line 24 h; D: 
End1/E6E7 cell line 48 h, (n=3). 
5.3.5 Mucoadhesion of the MPs 
       Mucus, which is secreted by epithelium of the cervix, plays an important role in 
female reproductive function by facilitating the wriggling of the sperm toward the uterus135. 
Mucus also provides a protective covering for the vaginal epithelium. It can be present as a 
luminal soluble, suspended form, or gel layer adherent to the mucosal surface136. Mucin 
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glycoprotein is the major components of mucus gels. In this study, the Mucoadhesion of the 
MPs is assessed through the adsorption of mucin by MPs. It is reported that the mucus 
compositional differences exist among individuals137. Even for the same person, the amount 
of mucin in the female reproductive tract changes during the menstrual cycle. Prior studies 
suggest that in healthy women, the daily production of cervix mucus is around 20–60 mg. 
During the midcycle, it increases up to 700 mg/day and becomes less viscous in order to 
allow sperm penetration138. Therefore different concentration of mucin, low (0.1 mg /ml), 
medium (1 mg/ml) and high (2 mg/ml) is selected, respectively. The results are shown in Fig. 
5-10, the mucin adsorption of the TCS coated MPs is increased by 10-20 fold Compare to 
that of the non-mucoadhesive MPs (alginate). In both VFS and SFS, the mucin adsorption is 
quite low, around 20%, when mucin concentration is relatively low (0.1 mg/ml), the possible 
reason is, both vaginal fluid and semen fluid contain soluble proteins, which is substituted by 
BSA in VFS and SFS. The negatively charged protein can interact with positively charged 
MPs by charge-charge interaction. With low mucin concentration, MPs have less chance to 
collide with mucin molecules, the protein occupies the surface of MPs and results in low 
mucin adsorption. When mucin and MPs has the same concentration (1 mg/ml), the mucin 
adsorption increases to approximately 50%. After the mucin concentration is increased to 2 
mg/ml, the percentage of mucin adsorption decreases to about 40% compare to that of the 1 
mg/ml solution, however, given the difference in concentration, it is reasonably computed 
that the amount of mucin adhered to the MPs in 1 ml of buffer is increased approximately 
from 0.5 mg to 0.8 mg. 
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Fig. 5-10 Mucin adsorption in VFS (A) and SFS (B), (n=3). 
5.3.6 In vivo safety studies 
       DLMPs, which show relatively high drug loading and slow release rate, are applied 
intravaginally to female C57/BL6 mice, the light micrographs of their genital tissues are 
analyzed.  A representative H&E stained vaginal tissue section is presented in Fig. 5-11. 
Daily intravaginal exposure to the DLMPs does not lead to significant microscopic 
abnormalities. As a comparison, severe histopathologic changes, including ulceration and 
denudation (red arrows)  evident among mice treated with 4% N-9 for 24h. The 
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substantive difference of the vaginal epithelium integrity is found to be insignificant due to 
the recovery of the vaginal epithelium after 24 h postapplication139. 
 
Fig. 5-11 H&E stain in vivo safety evaluation in C57BL/6 mice after 24 h (top row) and 7 
days (bottom row) exposure with PBS, DLMPs, and N-9. Scale bar = 0.1 mm. 
       Therefore, to determine whether the MPs treatment can induce the infiltration of 
immune cells, the distribution of CD45-positive cells is examined using IHC analyses, which 
is indicative of inflammation, into the cervico-vaginal mucosa. After 4% N-9 application for 
24 h and 7 days, Compare to the PBS treated tissue (negative control), the level of 
CD45-positive cells distributed within the N-9 treated vaginal epithelium is slightly elevated, 
Whereas the distribution of immune cells within the DLMPs treated vaginal tissue is similar 
to that of the negative control. The CD45-positive cells are identified by arrowhead marks in 
Fig. 5-12. The results indicate that there is no considerable inflammation of the vaginal 
epithelium after DLMPs exposure for 24 h and 7 days.  
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Fig. 5-12. Immunohistochemical stain in vivo safety evaluation in C57BL/6 mice after 24 h 
(top row) and 7 days (bottom row) exposure with PBS, DLMPs, and N-9. Scale bar = 0.1 
mm. 
5.4 Conclusions 
       In this study, a custom experimental design is used to optimize the formulation and 
process parameters of a spray dried alginate MP. Base on the optimized MP, thiolated CS 
coated multilayer MPs are prepared utilizing a layer-by-layer technique. These microspheres 
have non-cytotoxic to vaginal and endocervical epithelial cells, as well as high 
mucoadhesion property in both vaginal fluid and semen fluid. These data suggests that these 
MPs are effective for intravaginal delivery of anti-HIV microbicides.  
 
 
  
 117
CHAPTER 6 
TENOFOVIR CONTAINING THIOLATED CHITOSAN CORE/SHELL NANOFIBERS: 
IN VITRO AND IN VIVO EVALUATIONS 
6.1 Rational 
       The study of nanomedicine has been dominated by spherical particle design, mainly 
because it minimizes the interfacial energy during the particles formation140. However, very 
few non-spherical delivery systems are studied even though they could potentially exhibit 
superior properties. One of the most promising non-spherical delivery systems are 
nanofibers (NFs), which can be designed by electrospinning (ESP)141. ESP utilizes 
electrostatic forces as its driving force to produce polymeric fibers142. It provides an effective 
and alternative way to directly encapsulate both hydrophobic and hydrophilic drugs into the 
fibers directly143. Biocompatible polymers can be electrospun into nano-sized mesh that is 
composed of fibers with a high surface area144. The high surface-to-volume ratio of NFs 
makes them suitable for mucoadhesive drug delivery systems.  
       In this study, thiolated chitosan (TCS) is used as the mucoadhesive material in NF 
formulation. Its mucoadhesive property has been proven in various studies35a, 145. TCS on the 
surface of the formulation can bind to the mucosa, which lines the surfaces of body cavities, 
such as the vagina and rectum, to maintain a certain level of moisture146. Therefore, the 
adhesive property of a formulation is largely depended on its surface-to-volume ratio. 
Compare to spherical NPs, NFs have higher surface-to-volume ratio resulting in more 
interfacial area available to interactions thereby aiding the adhesion27, 147. Once applied 
topically, the mucoadhesive NFs intend to stay in close contact with the mucosa, prolong the 
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residence time on the application site, provides long-lasting protection to women148, since 
heterosexual contact is the major route of acquiring HIV for women26.  
       In this study, it is hypothesized that ESP can improve the drug loading significantly, 
in comparison with other forms of drug delivery systems produced by conventional methods, 
such as hydrogel, liposomes, and nanospheres149; the electrospun TCS NFs can provide 
long-lasting drug release due to their mucoadhesivity, and are safe in vivo.  
6.2. Materials and methods 
6.2.1 Materials 
       Chitosan (CS) (Mw 50-190 kDa), thioglycolic acid, poly(ethylene oxide) (PEO) 
(Mw 900 kDa), formic acid, mucin (Type III), periodic acid Schiff reagent kit and DAB: 
Peroxidase Substrate Kit are purchased from Sigma Aldrich (St. Louis, MO, USA). Poly 
(DL-lactide)  (PLA) (PDL 05) is a gift from Purac Biomaterials (Lincoln, IL, USA). 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and 
N-hydroxysuccinimide (NHS) and sodium triphosphate penta-basic (TPP) are supplied by 
supplied by Thermo Fisher Scientific (Pittsburgh, PA, USA). TCS is synthesized as 
described in the Supary material file. Tenofovir (TFV) is purchased from Zhongshuo 
Pharmaceutical Co. Ltd. (Beijing, China). The CytoTox-ONE™ and CellTiter 96™ Aqueous 
kits are purchased from Promega (Madison, WI, USA).  Anti-CD45 and biotinylated 
secondary antibody is obtained from Santa Cruz Biotechnology, Inc. (Dallas, Texas, USA). 
6.2.2 Methods  
6.2.2.1 Preparation of the TCS core/shell NFs 
        A blend of TFV and PEO is used as the core material. A coaxial spinneret is used 
to allow for the injection of PEO solution into the TCS solution as shell material at the 
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syringe tip.  
       The core composite solution is prepared by dissolving PEO into 50% v/v formic 
acid solution and stirring over night to yield a 3% (w/v) homogeneous solution. TFV is 
dissolved in the same solution at the concentration of 1% (w/v). To prepare the core 
composite solution, TCS is mixed with PLA in a ratio of 1:1 (w/w). Then, TCS or TCS-PLA 
blend is dissolved in pure formic acid at the concentration of 3% (w/v) and TPP is added in 
the solution at the ratio of TCS:TPP is 8:1 (w/w). 
        An electrospinning system with a coaxial nozzle (NaBond Technologies Co., Ltd., 
HongKong, China) is used for NF production. The core and shell composite solutions are 
placed in two separate glass syringes (Becton, Dickinson and Company, NJ, USA). Two 
syringe pumps (Cole-Parmer Instrument Company, IL, USA) are used to supply a 
continuous and constant amount of solution. The feeding rate of both the solutions is 50 μl/h. 
A voltage of 15 kV is applied to the nozzle by a high voltage power supply (Gamma High 
Voltage Research, Inc., FL, USA). The NFs are collected onto an aluminum collector 
connected to the ground. The distance between the collector and the syringe tip is 10 cm. 
After electrospinning, the prepared NF mat is peeled from the surface of the collector and 
stored in a vacuum desiccator. 
6.2.2.2 Percent drug loading and yield 
       To determine the drug loading, approximately 1 mg of TFV loaded NFs is 
submerged in 50 ml water for 48 h to allow complete dissolution of the PEO core and 
vortexed for 5 min. After centrifugation (Micro 18R Ultracentrifuge, VWR International 
LLC., PA, USA) at 10,000 rpm for 20 min, the supernatant is analyzed by using a high 
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performance liquid chromatography (HPLC) assay at 259 nm150. The percent drug loading is 
calculated by using Equ. 6-1: 
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       The yield of the NFs fabrication process is calculated by the ratio of total mass of 
the electrospun NFs to the total mass of the initial ingredients combined (Equ. 6-2). 
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6.2.2.3 Morphological analysis study  
       The morphology and surface characteristics of the NFs are analyzed by scanning 
electron microscopy (SEM) and transmission electron microscopy (TEM). For SEM analysis, 
small amount of NFs is mounted to aluminum stubs with conductive tape, and sputter coated 
with approximately 20 nm thickness of gold–palladium alloy. The NFs are then examined 
using a FEI/Philips XL30 Field- Emission Environmental SEM (Philips, Eindhoven, 
Netherlands) at 5 kV. Digital images are acquired with ORIUSTM SC 1000 11 Megapixel 
CCD camera (Gatan, Pleasanton, CA, USA). The SEM images are analyzed using Image 
Pro® Plus software (Image Pro Plus 6.0, Media Cybernetics, Silver Spring, MD, USA). The 
following measurements are made: average fiber diameter, average bead diameter, and the 
approximate ratio of bead area to total bead and fiber area.  
       For TEM analysis, NFs are deposited onto a copper grid with a carbon support film. 
The copper grid is submerged in water and then dried. The NFs are observed under a 
Scanning Transmission Electron Microscope CM12 (FEI, Hillsboro, OR, USA) at 80 kV 
accelerating voltage. Digital images are acquired as described above. 
6.2.2.4 Fourier transform infrared (FT-IR) spectroscopy analysis 
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       In order to elucidate the surface chemistry, the NFs are directly scanned over the 
range of 650 and 4000 cm−1. The background is collected at ambient conditions before 
analyzing each sample. The FT-IR spectra are recorded by OMNIC V 7.0 spectra software. 
6.2.2.5 In vitro drug release profile from the NFs 
        One milligram of NFs is immersed in a tube containing 40 ml of vaginal fluid 
simulant buffer (VFS), prepared according to previous reports45. The tubes are kept in a 
thermostatically controlled water bath (BS-06, Lab Companion, USA) at 60 rpm, the 
temperature is maintained at 37ºC. At predetermined time intervals, 1 ml of the VFS buffer 
solution is taken out and replaced by fresh buffer to maintain the sink conditions. The 
concentration of drug in the buffer solution is determined by the above HPLC assay. Each 
experiment is run in triplicate (n = 3) together with a blank control.  
6.2.2.6 In vitro cytotoxicity studies 
       Human vaginal keratinocyte cell line (VK2/E6E7) and human endocervical 
epithelial cell line (End1/E6E7) are grown in the Keratinocytes-SFM medium, the media is 
Suped with 10% (v/v) fetal bovine serum (FBS) and 1% penicillin/streptomycin. Cells are 
cultured at 37°C in a humidified 5% CO2 atmosphere and sub-cultured prior to confluence 
using trypsin.  Lactobacilli crispatus is grown in an ATCC medium 416 Lactobacilli MRS 
broth (BD, Franklin Lakes, NJ, USA) and cultured at 37°C in a humidified 5% CO2 
atmosphere. 
6.2.2.7 Cell culture 
6.2.2.7.1 Cellular membrane integrity assay 
       The NFs membrane with an area of 0.25 cm2 (approximately 0.1 mg), is peeled 
from the collector and laid at the bottom of each well in the 96-well plates. VK2/E6E7 and 
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End1/E6E7 cell lines are seeded in the plates with the NF membrane to ensure 1 × 104cells 
per well. The plates are then incubated at 37°C for 24 or 48 h. The cells incubated with 
media alone or 1% Triton X-100 (both without NFs) are used as the negative and positive 
controls, respectively. 
        To measure the lactate dehydrogenase (LDH) release, after the 24 or 48 h 
incubation time, the plates are taken out of the incubator and equilibrated to 22 °C. In each 
well, 100 μl of CytoTox-ONE™ Reagent is added. The plates are shaken for 30 s and then 
incubated at 22 °C for 10 min. After this, 50 μl of stop solution is added and the fluorescence 
intensity is determined by a microplate reader at λex 560 nm and λem 590120c.  
6.2.2.7.2 Cell viability assay 
       To determine the cell viability, after the incubation time, the media in the wells is 
removed and substituted with fresh media. Twenty microliters of Cell Titer 96®Aqueous One 
Solution Reagent (Promega, Madison, WI, USA) is added to each well and incubated at 
37°C for 4h. The absorbance is recorded at a wavelength of 490 nm.  
6.2.2.7.3 Lactobacillus viability assay 
       The Lactobacillus viability assay is performed using an established method47. The L.
crispatus bacteria density is adjusted to an OD670 of 0.06, corresponding to a 0.5 McFarland 
Standard or 108 CFU/ml48a. It is then plated in the plates with NFs at a volume of 100 μl per 
well, and then incubated at 37 °C. The Lactobacillus incubated without NFs is used as the 
negative control and those incubated with a commercially available 10 μg/ml of 
Penicillin-Streptomycin solution (Invitrogen, Carlsbad, CA, USA) is used as a positive 
control. After 24 or 48 h, 20 μl of MTS reagent is added to each well, and the bacterial 
viability is determined by measuring the absorbance at a wavelength of 490 nm by a 
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microplate reader.  
6.2.2.8 Mucoadhesion study 
       A periodic acid/Schiff (PAS) colorimetric method is used to determine the free 
mucin concentration in order to assess the amount of mucin adsorbed on the NFs127. Periodic 
acid reagent is freshly prepared by adding 10 μl of 50% periodic acid solution to 7 ml of 7% 
(v/v) acetic acid solution. One milligram of PEO, PEO/TCS, and PEO/TCS-PLA NFs is 
added in the mucin solution of VFS at the concentration of 1 mg/ml. The solution is 
incubated in a shaking water bath for 30 min at 37°C to enable NFs-mucin interaction. Then, 
the dispersions are centrifuged at 4000 rpm for 2 min to separate NF-mucin conjugate, and 
the supernatant is used for the measurement of the free mucin content. For each sample, 0.2 
ml of periodic acid reagent is added, the samples are incubated at 37°C for 2 h in a water 
bath. Then, 0.2 ml of Schiff reagent is added at room temperature. Thirty minutes later, the 
absorbance of the solution is recorded at 555 nm by using the Genesys 10 Bio UV–Vis 
Spectrophotometer (Thermo Electron Sci. Inst., LLC, Madison, WI, USA). Standard 
calibration curve is prepared from 1 ml of mucin standard solutions in the concentration 
range of 0.25 - 2 mg/ml. The mucin content is calculated from the standard calibration curve. 
The mucin solution without NFs is used as a control and assessed using the above procedure. 
Each experiment is performed in triplicate (n = 3). The percentage of mucin adsorption is 
estimated using Equ. 6-3: 
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       The above method is developed for the quantification of the mucoadhesion, 
however, it is limited due to no biological tissue is used. To assure the NFs can adhere to the 
real vaginal mucus, an infusion method is employed. The porcine vaginal tissues are 
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obtained from the local abattoir (Fairview Farm Meat Co., Topeka, KS, USA). These tissues 
are washed using normal saline, snap frozen in liquid nitrogen, and then stored at -80°C. 
Before the experiment, the frozen tissues are thawed in normal saline at 37°C for 3 min. the 
FITC labeled TCS is synthesized as previously described50. The tissue is cut into pieces of 2 
cm length and 1 cm width and stuck to a plastic strip by cyanoacrylate glue, which is 
resistant to water and harmless to the tissue. Approximately 0.1 mg of FITC labeled 
PEO/TCS and PEO/TCS-PLA NFs are distributed over the surface of the tissue. The strip is 
put into a tube that is placed in a water bath of at an angle of 75° to allow buffer flow by 
gravity. The tissue is then placed in a container maintains at 37°C and relative humidity for 
20 min to allow the NFs to hydrate and to interact with the mucin layer of the tissue. After 
20 min, the mucosa is continuously washed for 10 min with VFS at the rate of 1 ml/min. The 
tissue is then cut into small cubes, embedded into Histoprep, frozen by liquid nitrogen, and 
sectioned vertically using a cryostat microtome. The skin sections (5 mm) are mounted on 
glass slides and visualized through a fluorescence microscopy (Nikon, Shizuoka Prefecture, 
Japan)89. 
6.2.2.9 In vivo safety studies  
       The animal experiments are duly approved by the University of Missouri - Kansas 
City Institutional Animal Care and Use Committee (IACUC). Female 8-12 weeks old 
C57Bl/6 mice, weighing about 18-22 g, are obtained from Jackson Laboratories (Bar Harbor, 
Maine, USA.) and allowed to acclimate for 7 days. All mice are housed (no more than 5 per 
cage) under a 12 h light: dark regime in the University of Missouri-Kansas city (UMKC) 
Laboratory Animal Resource Center (LARC) facility which is a fully AAALAC accredited 
with HEPA-filtered, temperature, humidity, and lighting controlled systems. In order to 
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maintain a constant diestrus-like vaginal cytology for reproducible experimental conditions, 
mice are s.c. injected with 2 mg of medroxyprogesterone acetate (Depo-Provera®, 
Greenstone, Peapack, NJ, USA)) in a total volume of 200 μl of in Lactated Ringer’s saline 
solution 4-5 days before the treatment to induces and maintain a diestrus-like state..  
       The mice are divided randomly in three groups (n = 4). Group 1 is treated with 20 
μl Benzalkonium chloride (BZK, 2 %w/v), as positive control; group 2 is treated with PBS is 
used as negative control; group 3 is treated with freshly prepared PEO/TCS-PLA NFs , the 
dose is 475 mg/kg. Intra-vaginal instillation is carried out Once daily using a flexible feeding 
needle (Cadence, Inc. Staunton, VA, USA). After 1-day and 7-day intravaginal application, 
mice are euthanized by carbon dioxide (CO2) asphyxiation. Their vaginal tissues are 
collected, formalin fixed in paraffin, and cut into 5-mm sections.  
6.2.2.9.1 Hematoxylin and eosin (H&E) staining 
       Serial sections are stained with hemotoxylin and eosin (H&E). Images are captured 
using a Nikon Labophot-2 microscope (Nikon Instruments, Inc., Melville, NY) equipped 
with a PAXCam digital microscope camera and analyzed using PAX-it image management 
and analysis software (Midwest Information Systems, Inc., Villa Park, Illinois). 
6.2.2.9.2 Immunohistochemical staining 
       To identify the inflammatory cell (CD45) infiltrate, immunohistochemical staining 
is performed in genital tissue sections. Briefly, the de-paraffinized and rehydrated tissue 
sections are pretreated with citrate buffer/0.05%Tween-20 (antigen retrieval reagents) for 20 
min using steam heat method, rinsed with Tris buffered saline/0.05%Tween-20 three times, 
incubated with 3% v/v hydrogen peroxide in PBS for 10 min, and blocked with 10% normal 
goat serum (Vector Laboratories, Burlingame, CA) for 2 h. The slides are then incubated 
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with the primary anti-CD45 antibody overnight in a humidified chamber at 4°C, rinsed three 
times with PBS, followed by application of biotinylated secondary antibody at room 
temperature for 1 h. The cells are visualized using the DAB: Peroxidase Substrate Kit under 
a Nikon Labophot-2 microscope. The tissue is then counter-stained by hematoxylin (Sigma, 
Saint Louis, MO) and treated with alcohol gradient and xylene before application of a 
coverslip mounted using cytoseal 60 mounting media (Richard Allan Scientific, Kalamazoo, 
MI). Images are viewed and captured as described above.
6.2.2.10 Statistical data analysis 
       The results are expressed as the mean of at least 3 experiments (n=3) ± the standard 
error of the mean (SEM). Statistical data analysis is performed using the student t-test; two 
tails with 95% confident interval (p < 0.05) as the minimal level of significance. 
6.3 Results and discussions 
6.3.1 Formulation of NFs 
       Electrospinning is a simple, flexible, and cost-effective process that can form a 
broad range of polymeric fibers. During the electrospinning process, when a sufficiently high 
electrical potential is applied to the droplet of polymer solution, the droplet becomes charged. 
At a critical voltage, the electrical energy overcomes the surface energy of the polymer 
droplet, and a jet erupts from the surface. The jet is then elongated under the electrostatic 
force while the solvent of the polymer is being evaporated until it is finally deposited on a 
grounded collector151. 
       TCS is a derivative of CS, it presents on the surface as the shell can interact with the 
mucosa while the TFV is released from the core in controlled manner. CS is a cationic 
polysaccharide. The amino groups on the polymer backbone are ionizable and positively 
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charged under acidic condition. During the electrospinning process, the repulsive force 
between ionic amino groups within polymer backbone limit its electrospinnability and 
inhibits the formation of continuous fiber under the high electric field152. Therefore, the 
electrospinning of pure TCS typically forms beads and droplets instead of ultrafine fibers153. 
To overcome this drawback and obtain continues fiber, the following three alternative 
strategies are used.   
       Firstly, TCS is blended with Polylactic acid (PLA), which is a biodegradable 
aliphatic polyester. PLA has been approved by the FDA for human clinical applications, and 
has excellent film forming mechanical properties, attractive molding and shaping properties. 
It can be fabricated into porous NFs and many other types of structures154. Some works have 
been devoted to manufacture PLA/CS composites155. In our preliminary study, it is observed 
that the obtained NFs became more uniform when equal amounts of TCS and PLA are used. 
       Secondly, formic acid is the solvent of choice. This could be attributed to several 
reasons. 1) Formic acid is a good solvent of PLA/TCS composite, both TCS and PLA are 
soluble in formic acid. 2) The TPP is used to cross-link CS via charge-charge interaction 
between the phosphate groups of TPP and the amino groups of CS38. The crossing linking is 
dependent on the availability of the cationic sites and the anionic sites. CS is polycationic in 
acidic environment, TPP has 5 pKa values as follow156:  
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       Since the pH of pure formic acid is lower than 1, only H
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ions are present, the 
negative charge is too low to cross-link the positively charged CS. TPP and CS are free in 
the solution. After electrospinning, when the NFs are immersed in the VFS (pH 4.2), both 
CS and TPP dissociate to provide sufficient cationic sites and the negative sites, not until 
then will they crosslink and form the insoluble shell. This is supported by the fact that the 
solution of CS and TPP in pure formic acid is dropped into water or VFS, it precipitates as 
white flocky sediment (Fig. 6-1). 3) CS solution has high viscosity, which limits its spin 
ability157. As a comparison with other solvent of CS, such as acetic acid (intrinsic viscosity 
[η] = 28.21×102 dL/g), the viscosity of the solution of CS in formic acid (intrinsic viscosity 
[η] = 6.72×102 dL/g) is relatively low at equal concentration158. This facilitates the formation 
of the jet during the electrospinning process. 4) The vapor pressures of formic acid and 
acetic acid is 45 mm Hg and 11 mm Hg at 20 °C, respectively159. The high volatility of 
formic acid is also advantageous for the rapid solidification of the electrified jet.  
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Fig. 6-1. Ionization of CS and TPP blend from formic acid to water.  
       Thirdly, PEO serves not only as a core material, but also a spinning aid. The PEO 
core solution is believed to act as a carrier that form a stable Taylor cone and draws out the 
shell CS solution by forming a continuous jet ejection160. Moreveer,PEO is nontoxic and has 
been approved by the FDA for use in different pharmaceutical formulations161. To 
successfully prepare the core/shell NFs, 50% formic acid is used as the solvent of PEO. 
Using the same solvent in the two streams can reduce the interfacial tension between the two 
solutions. The surface tension of 50% formic acid at 20 °C is 43 dyn/cm, very close to that 
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of the pure formic acid (37 dyn/cm at 20°C)162, it is in favor of coaxial electrospinning163. If 
water (72 dyn/cm at 20°C) is used as the core solvent instead of acid solution, it appears that 
no fiber can be formed. This result is also confirmed by Pakravan et al.160.  
NF drug loading and percent yield 
       As shown in Tab. 6-1, the drug loading of the PEO, PEO/TCS and PEO/TCS-PLA 
NFs are 25.62%, 13.42% and14.20% w/w, which is in close agreement with the theoretical 
values. Their respective yields are 102.48%, 53.65% and 63.18%. The jet stretches by 
whipping and bending. The nature of the whipping motion and bending instability of the 
charged jet in the electrospinning process may cause some shift in the direction, and 
distribute the fibers over a larger area. For PEO/TCS and PEO/TCS-PLA NFs, the area of 
NFs deposit exceeds that of the collector, not all the NFs can be collected on the aluminum 
foil, which lead to a lower yield (Tab. 6-1).  
Tab. 6-1 Composition, drug loading, yield and mean diameter of the NFs. Data are given as 
mean ± SEM for n=3. 
NF Component Drug 
loading (%) 
Yield (%) Mean 
diameter of 
fibers (nm) 
Core  Shell 
PEO NF PEO  N/A 25.62±0.93 102.48±0.95 118.56±4.77 
PEO/TCS NF PEO  TCS 13.42±3.51  53.65±0.26   9.95±0.64 
PEO/TCS-PLA 
NF 
PEO  TCS PLA 
blend 
14.20±2.12  63.18±1.16  99.52±5.52 
 
6.3.2 Morphology studies 
 131
       The SEM images (Fig. 6-2) shows that the pure PEO fibers and the core-shell fibers 
has been successfully produced using the electrospining technique. All the electrospun NFs 
are in nanoscale size in diameters. To characterize the NFs, the average fiber diameter, 
average bead diameter, and the approximate ratio of the bead area to the total NFs area are 
summarized in Tab. 6-1. Both PEO and PEO/TCS-PLA NFs are highly smooth without the 
occurrence of beads. However, for the PEO/TCS NFs, beads with the mean diameter of 
58.81 nm are observed. Besides the morphological difference, there is also a difference in 
diameter between the pure PEO NFs and the PEO/TCS ones. The mean diameters of the 
PEO, PEO/TCS and PEO/TCS-PLA NFs are 118.56 nm, 9.95 nm and 99.52 nm, respectively. 
Compared to the pure NFs, the diameters of the PEO/TCS core shell NFs are significantly 
lower due to the strength of the repulsive force as explained above. The incorporation of 
PLA into the TCS shell solution leads to continuous, defect-free, cylindrically-shaped fibers. 
The NFs which are significantly uniform without beads are observed again. 
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Fig. 6-2. Morphology of the nanofibers (NFs). Scanning electron microscopy (SEM) image 
of PEO NFs (A), PEO/TCS NFs (B), PEO/TCS-PLA NFs (C), Transmission electron 
microscopy (TEM) image of PEO/TCS NFs before PEO core extraction (D), PEO/TCS-PLA 
NFs before PEO core extraction (E), PEO/TCS NFs after PEO core extraction (F), 
PEO/TCS-PLA NFs after extraction (G). Scale bar = 2 μm for SEM, scale bar = 200 nm for 
TEM. 
       To further identify the core/shell structures, the morphological detail of the 
produced core/shell NFs is shown in a TEM micrograph in Fig. 6-2 D-G. The contrast, 
which represents the distinctive phases in the NFs, is due to the absorption of electron beam 
in the organic molecules with different electron density used in TEM samples164. In Fig. 6-2 
D and E, the bright and dark regions represent the shell and core of the NFs, respectively. 
The electrospun NFs are soaked in water in order to selectively remove the PEO, since the 
water is a good solvent for PEO but poor solvent for TCS and TCS-PLA blend. The NFs are 
then examined under the TEM, the resulting structure is shown in Fig. 6-2 F and G. It 
appears that the PEO/TCS NFs are broken after aqueous extraction; fragments of the NFs 
instead of intact fibers are observed, revealing a discontinuous core–shell structure. 
Comparatively, the PEO/TCS-PLA NFs show very uniform core–shell structure with 
obvious boundary: the core is about 30 nm in diameter while the shell is approximately 20 
nm in thickness. After the core (dark region) is completely removed, an integrated hollow 
fiber is observed. According to the SEM and TEM image, it is speculated that the PEO/TCS 
NFs have a necklace-like structure (Fig. 6-3 A), where TCS beads of different size are on the 
PEO string. Unlike PEO/TCS NFs that have a fine core/shell structure (Fig. 6-3 B), PEO is 
mainly located in the core while TCS-PLA blend constitutes the shell. 
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Fig. 6-3. Schematic description of PEO/TCS nanofibers (NFs) (A) and PEO/TCS-PLA NFs 
(B). 
6.3.3 FTIR analysis 
       Fig. 6-4 displays the FTIR spectra of native PEO, TCS, PLA and the core/shell NFs. 
The native PEO shows a characteristic band at 2890 cm−1 corresponding to the CH2 
stretching vibration, which overlaps with that of CS. Absorption bands of hydroxyl (-OH) 
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groups are negligible as a high molecular weight (900 kDa) PEO is used. Other feature 
bands of PEO observed from 1240 to 1360 cm–1 are due to CH deformation of the methyl 
groups (-CH3). The triplet peaks at 1065, 1095 and 1150 are referred to C−O−C stretching 
vibrations165. The native TCS exhibited a broad absorption peak at around 3100 to 3650cm–1 
and weak absorption peaks at 2890 cm–1, which are attributed to N-H and OH-O (hydrogen 
bond) stretching vibration and the CH stretch, respectively. The two peaks at 1520 and 1650 
cm–1 are respectively due to the amide (CO-NH-) and the amine (-NH2) absorption band. 
The FTIR spectra of native PLA reveals a sharp peak at 1750 cm−1 and characteristic bands 
from 1050 to 1200 cm−1, 1187, 1131 and 1093 are assigned to the ester groups (-CO-O-) of 
PLA155a . The peak of 1758 cm−1 which belonged to the carbonyl group in PLA is decreased. 
       In the spectrum of the PEO/TCS NFs, the absorbance intensity of amide and amine 
groups stretching at 1520 and 1650 cm-1 is decreased and the absorbance intensity of CH2 
stretching vibration at 2890 cm-1 is increased, indicating that the PEO exists not only in the 
inner core, but also on the surface of the NFs. For the PEO/TCS-PLA NFs, the increasing of 
the peak at 2890 cm-1 is not apparent, three characteristic bands at 1520, 1650 and 1750 cm-1 
are observed, suggesting that the shell of these NFs are composed mainly of TCS and PLA, 
no PEO or perhaps a very minute quantity of PEO distributes on the surface of the NFs due 
to the fine core–shell morphology. 
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Fig. 6-4 The FT-IR reflectance spectra of neat PEO, TCS, PLA powder, PEO/TCS and 
PEO/TCS-PLA nanofibers (NFs).  
6.3.4 In vitro drug release study 
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       The drug release profiles for the NFs are shown in Fig. 6-5. In order to compare 
release kinetics of PEO NFs and the core/shell NFs, a simple model independent approach of 
FDA guidance is applied.  The difference factor (f1) and similarity factor (f2) are calculated 
as follow: 
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       Where n is the number of time points, Rt and Tt are the cumulative degradation and 
drug release (%w/w) at time t for reference (PEO NFs) and the test formulation (PEO/TCS 
NFs or PEO/TCS-PLA NFs), respectively67. 
        Here f1 is a measurement of the percent difference between the reference and test 
sample at each time point, while f2 calculates the similarity in the percent dissolution 
between the two samples. Two curves can be considered similar if the values of f1 and f2 are 
close to 0 and 100, respectively. In this study, f1 values of PEO/TCS and PEO/TCS-PLA NFs 
are 41.23 and 56.73; f2 values are 8.24 and 1.31, respectively, indicating significant 
difference between the PEO NFs and the core/shell NFs. 
        For the PEO NFs, approximately 95% of drug is released within 5 h, which is 
attributed to the hydrophilic nature of PEO; the mechanism of drug release is based on 
dissolution of the drug. In the case of PEO/TCS and PEO-TCS-PLA NFs, The release 
profiles are simulated to a series of known release kinetic models: first-order model, Higuchi 
model, Korsmeyer-Peppas model, and Weibull model166, The model with the highest 
determination coefficient (R2) is chosen as the best fit, data is analyzed using the Excel 
add-in DDSolver program126. It appears that they both follow Weibull model, R2  = 0.983 
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and 0.991 for PEO/TCS NFs and PEO/TCS-PLA NFs, respectively. Weibull model is 
commonly used to describe the release profiles of matrix type delivery system. Given the 
fact that the effective molar EC50 of TFV is 5.0 to 7.6 μM, if the concentration of the NFs in 
VFS is 1 mg/ml, it is equivalent to a TFV concentration of 350 μM bases on the average 
drug loading (~10%), which means the drug could exhibit its effect when approximately 1.4% 
of drug is released from the NFs. According to the predicted release profiles in Fig. 6-5, both 
PEO/TCS and PEO/TCS-PLA NFs could release 1.4% of TFV within 2 min after application. 
Therefore, it is reasonable to speculate that both NFs are able to provide sufficient TFV 
concentration to exhibit an anti-HIV activity.  After 24h, more than 80% of the drug is 
released from the PEO/TCS NFs, whereas approximately 60% of the drug is released form 
the PEO/TCS-PLA NFs. The release rate of the former is faster due to its discontinuous 
core–shell structure. Over all, the PEO/TCS-PLA NFs provide a better control on the drug 
release. 
 
Fig. 6-5. In vitro drug release profiles from PEO nanofibers (NFs), PEO/TCS NFs, and 
PEO/TCS-PLA NFs in vaginal fluid simulant buffer (n = 3). Data are shown as mean ± SEM 
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(n = 3).  
6.3.5 Cytotoxicity assays 
       A vaginal drug delivery system must have safety profiles that justify its application, 
especially for the vaginal ecology167. Thus, it is important to test the impact of the 
drug-loaded NFs on the viability and structural integrity of the vaginal epithelial cells as well 
as the natural flora in the vagina. The cellular membrane integrity is determined by the 
release of lactate dehydrogenase (LDH) from cells with damaged membranes. MTS is a 
tetrazolium compound that is convertible into a brown colored formazan product by viable 
cells with active metabolism, the amount of formazan produced is proportional with the 
number of viable cells99. Fig. 6-6 A-D shows the results of the LDH release and the cellular 
viability (MTS assay) using the selected vaginal epithelial (VK2/E6E7) cell line and human 
endocervical epithelial (End2/E6E7) cell lines. After 24 h or 48 h, the TFV loaded NFs cause 
a statistically non-significant (p>0.05) release of LDH as a comparison with that caused by 
the media. The cellular viability test results are consistent with those of LDH assay, as no 
statistical difference (p>0.05) is observed by the Student t-test between the media and the 
TFV loaded NFs. The Lactobacillus viability assay (Fig. 6-6 E-F) also shows that no 
statistically significant loss of bacterial viability is observed during the incubation period. 
       The results indicate a non-cytotoxic nature of the NFs on both vaginal and 
endocervical epithelial cell lines and the vaginal flora at the concentration of 1 mg/ml up to 
48 h.21a 
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Fig. 6-6 Cytotoxicity study of PEO nanofibers (NFs), PEO/TCS NFs, and PEO/TCS-PLA 
NFs. CS and TCS NPs. LDH release of VK2/E6E7 cell line (A) and End1/E6E7 cell line (B), 
percent viability of VK2/E6E7 cell line (C) and End1/E6E7 cell line (D), percent viability of 
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L.cripatus after incubated with the NFs for 24 h (E) and 48 h (F). Data are shown as mean ± 
SEM (n = 3). *: p<0.05 vs media, **: p<0.01 vs media. 
6.3.6 Mucoadhesive studies 
       The enhanced mucoadhesive property of the core/shell NFs is based on the 
covalently attaching of thio-glycolic acid thiolation to CS backbone. TCS displays thiol side 
chains that mimic the natural structure of the secreted mucus glycoproteins. These side 
chains can form disulfide bound with the cysteine-rich subdomains of mucin via 
thiol/disulfide exchange reactions or a simple oxidation process of free thiol groups. As a 
result, TCS can covalently anchor in the mucus layer29-30.   
       The PAS technique is a widely employed colorimetric assay for the demonstration 
of mucin. The periodic acid solution is used as the oxidant. The periodic acid oxidizes the 
hydroxyl (OH) groups in the monosaccharide units of mucin, thus generating Schiff reactive 
aldehyde groups. These free aldehyde groups then react with the Schiff reagent to give a 
bright red magenta color. In this study, low (0.2 mg /ml), medium (1 mg/ml), and high (2 
mg/ml) concentration of mucin is selected, due to the fact that the amount of mucin changes 
in the female reproductive tract during the menstrual cycle, the daily production of cervix 
mucus in a healthy woman is around 20–60 mg, which increases up to 700 mg/day and 
becomes less viscous During the midcycle, the mucus compositional differences also exist 
among individuals138. As shown in Fig. 6-7, the proportion of mucin adsorption of 
PEO/TCS-PLA NFs is similar to that of PEO/TCS NFs. The possible reason is that the 
thiolated groups exposed at the surface of the PEO/TCS-PLA NFs are no less than that 
exposed at the surface of the PEO/TCS NFs, since TCS forms discontinuous, large, or small 
beads while TCS-PLA blend forms continuous and uniform fiber shell. In contrast, little 
 142
mucin is adsorbed on PEO NFs. These results confirm that both PEO/TCS and 
PEO/TCS-PLA NFs have the ability to adsorb mucin and potentially enhance mucoadhesion 
in vivo. 
Fig. 6-7 Adsorption of mucin on PEO, PEO/TCS and PEO/TCS-PLA nanofibers (NFs). 
       The mucoadhesion of PEO/TCS and PEO/TCS-PLA NFs are assessed following the 
infusion procedure. As illustrated in Fig. 6-8, after rinsing using VFS, the fluorescence 
intensity of both NFs is not markedly reduced. Both NFs are spontaneously adsorbed to the 
surface of the porcine vaginal tissue, as a strong interaction exists between TCS and mucin. 
Moreover, the interconnected NFs inseparably associates with each other, and thus 
constituting a network, even if part of NFs is detached from the tissue the integrated network 
would not peel off. These results confirm that both PEO/TCS and PEO/TCS-PLA NFs are 
resistant to vaginal fluid and subsequently might increase the retention time in vivo. 
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Fig. 6-8 Fluorescence microcopy of thin sections of porcine vaginal tissue treated with 
PEO/TCS nanofibers (NFs), PEO/TCS-PLA NFs, and VFS without NFs before (top row) and 
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after (bottom row) rinsing by vaginal fluid simulant buffer. Scale bar = 0.1 mm. 
6.3.7 In vivo safety studies in C57Bl/6 mice. 
       In order to determine whether the exposure of the MPs results in inflammation and 
toxicity to the vaginal mucosa, the H & E stained vaginal sections of the mouse are 
evaluated. The PEO/TCS-PLA NFs contain the equivalent to approximately 65 mg/kg TFV, 
it has greatly exceeded the effective dose, 8 mg/kg, after convertion from the effective 
human dose (40 mg/person)23b base on body surface area (BSA) normalization method168.  
Fig. 6-9 shows the representative mice treated with NFs daily. Light microscopic 
examination indicates intact vaginal epithelium and lack of leukocyte influx in the 
representative vaginal sections from mouse treated with NFs daily for 1 day (Fig. 6-9 top 
row), and 7 days (Fig. 6-9 bottom row). In contrast, vaginal tissue sections following daily 
intravaginal administration of with 2% BZK (positive control), due to its well-known toxic 
effects on genital tracts, reveals extensive denudation of the epithelial cell layer and 
leukocyte infiltration (red arrows in Fig. 6-9)169. 
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Fig. 6-9 H&E stain in vivo safety evaluation in C57BL/6 mice after 24 h (top row) and 7 days 
(bottom row) exposure with PBS, PEO/TCS-PLA nanofibers (NFs), and Benzalkonium 
chloride (BZK). Scale bar = 0.1 mm. 
       The CD45-associated protein is a lymphocyte-specific membrane protein. The 
increasing of the lymphocytes infiltration within the vagina epithelium indicates the vaginal 
inflammation139. The CD45-positive cells distribution is studied using IHC analyses. In order 
to determine whether MPs treatment induced an infiltration of immune cells, After NFs 
application the distribution of CD45 positive cells in the vaginal tissue and the integrity of 
the vaginal epithelium is similar to that of PBS-treated (negative control) tissues, the number 
of the CD45-positive cells is elevated within the tissue treated by the 2% BZK as the red 
arrows shown in Fig. 6-10. 
 
Fig. 6-10 Immunohistochemical stain in vivo safety evaluation in C57BL/6 mice after 24 h 
(top row) and 7 days (bottom row) exposure with PBS, PEO/TCS-PLA nanofibers (NFs), 
and Benzalkonium chloride (BZK). Scale bar = 0.1 mm. 
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6.4 Conclusion 
       In the previously reports, various TFV loaded nanomedicines are prepared with low 
EE% and drug loading due to the high hydrophilicity of TFV. In this study, the novel TFV 
loaded electrospun nanofibers are developed consisting PEO, TCS and PLA to enhance its 
EE%. The obtained NF can be considered as a core-shell structure, with 13% to 25% drug 
loading, sustained release, non-cytotoxic nature, and enhanced mucoadhesion. The in vivo 
toxicity studies indicates local non-physiological or toxicity effects. 
       Owning to these promising properties, TFV loaded NF can be considered as a good 
candidate for the delivery of water-soluble small-molecule drugs, and a promising vaginal 
delivery system for the prevention of HIV transmission. 
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CHAPTER 7 
SUMMARY AND CONCLUSIONS 
7.1 Summary 
       Women are more susceptible to HIV infection in comparison with men due to not 
only the human physiology, but also social, economic, and legal disadvantages. To protect 
women from HIV transmission, there is an urgent need to develop a formulation for the 
topical application of anti-HIV microbicides. The conventional vaginal formulations, such as 
gel, tablet, and suppository, and suppository, are either lack the controlled release of drug 
substance or proper vaginal retention time. These limitations result in low acceptability and 
adherence of the patients to the dosage regime. However, these problems may be solved by 
novel nanomedicines. The aim of this dissertation is to test the hypothesis that a 
mucoadhesive polymer based nanomedicine can prolong the contact time with the vaginal 
tissue, provide the controlled release of the drug, and is safe in vivo. Various formulation and 
are investigated, their physicochemical properties, mucoadhesive properties, and safety are 
evaluated.  
       In Chapter 3, the size of chitosan (CS) nanoparticles (NPs) ranged from 168 nm to 
277 nm. When 50% (v/v) ethanol is used as a solvent, the percent encapsulation efficiency 
(EE%) increases from 7% to 20%, the drug loading increased form 0.20% to 1.14% (w/w). 
However the size was also increased to 580 nm (n=3). It is shown that NPs are safe to both 
vaginal epithelial cell line and Lactobacillus over 48 hours. When the diameter of the NPs 
decreases from 900 nm to 188 nm, the mucoadhesion increases from 6% to 12%. Overall, the 
CS NPs are mucoadhesive and safe as a microbicide carrier, the drawback of the CS NPs is 
the low EE%.  
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       In Chapter 4, the TFV loaded thiolated chitosan (TCS) NPs are prepared by ionic 
gelation. The particles are spherical with diameters ranged from 148 nm to 255 nm. The EE% 
and drug loading is 25% and 1.62% (w/w), respectively. The NPs provide a controlled release 
over of the drug following Higuchi model. The TCS NPs are not cytotoxic to both vaginal 
epithelial cell line and Lactobacillus over 48 h. The cellular uptake is time dependent. It is 
mainly occurred via caveolin mediated endocytosis. The mucoadhesive properties of TCS 
NPs is 5-fold higher than that of CS NPs. Compare to the CS NPs, the TCS NPs exhibit 
relatively higher EE%, drug loading, and mucoadhesion. 
In Chapter 5, the microparticles (MPs) are successfully formulated with an average 
diameter ranges from 2 μm to 3 μm with a drug loading of 7-12% (w/w). The MPs show a 
controlled drug release in both vaginal and seminal fluid simulant buffers. The MPs are 
found to have a high mucoadhesion (~50 folds at a higher ratio, and ~20 folds at a lower ratio 
of mucin: MPs) compare to non-layered sodium alginate MPs in both vaginal fluid and 
semen fluid simulant buffers. The multilayer MPs are non-cytotoxic to vaginal and 
endocervical epithelial cells. Histological analysis of the female C57BL/6 mice genital tract 
and other organs shows no damage upon once-daily administration of MPs up to 24 h and 7 
days. The drug loading of the TCS MPs is significantly enhanced (from 1.62% to 12.73%) 
compare to that of the TCS NPs. However, the mucoadhesion of the MPs is slightly lower 
than that of the NPs due to the larger particle size. 
       In chapter 6, the TCS core/shell nanofibers (NFs) are fabricated by a coaxial 
electrospinning technique. The drug loading is13%-25% (w/w), the EE% is about 100% 
because no loss of material during the electrospinning process. The NFs exhibit smooth 
surface with average diameters in the range of 50 to 100 nm. The NFs are non-cytotoxic at 
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the concentration of 1 mg/ml. The core-shell NFs exhibit a release kinetic following Weibull 
model, and are 40-60 fold more bioadhesive than NFs made solely with PEO. H&E and 
immunohistochemical (CD45) staining analysis of genital tract indicates non-toxicity and 
non-inflammatory effects of the NFs daily treatment for up to 7 days. The TCS NFs exhibit 
both high drug loading and high mucoadhesion; these data highlight the potential of TCS 
NFs templates for the topical vaginal delivery of anti-HIV/AIDS microbicides. 
7.2 Future perspective 
       The application of the nanomedicines to the vagina may be beneficial to patients by 
causing much less discomfort and reducing the frequency of the administration 
simultaneously. However, further in-depth studies of this drug delivery system are needed. 
Can these nanomedicines delivery other small molecular and biological microbicides, such as 
maraviroc and sifuvirtide? What is the effectiveness of the antiviral activity of the 
nanomedicines? What is the retention time of the TCS nanomedicines in the body of animals? 
What is the longer term effect of the formulations to vaginal tissue? There are numerous 
questions that are exigent to be answered. 
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